2010 09 19
For a summary of my most important merits please see page 13-14.
Peter M. Nilsson, MD, PhD
Born 7th October, 1953. Married, four children.
Office addresses:
1. Department of Clinical Sciences , Lund University, University Hospital, Gate 33,
S-205 02 MALMÖ, Sweden. Phone: office +46-40-33 24 15, Fax +46-40-92 32 72
2. Department of History of Medicine, University hospital, S-221 85 LUND, Sweden. e-mail : Peter.Nilsson@med.lu.se
1. Personal education and academic positions
Statistical education.
1972 (Faculty of Philosophy, University of Gothenburg). Four months of research-applied statistics (20p). Research courses in medical statistics.
Medical education.
1973-1979 (Medical Faculty, University of Lund), Internship in Kalmar
1979-1981, Specialisation in Kalmar 1981-1985. Specialist in General Medicine (1985).
Specialist in
Social Medicine
(1992).
Doctor of Medicine 1991-11-01 (MD, PhD). Thesis: "Metabolic disturbances in primary hypertension. Special focus on the non-pharmacological treatment of hyperinsulinemia" .
University of Lund, Sweden.
Associate professor ("docent"), 1994. Number of original publications: 199 published or accepted original papers in English, in peer-reviewed medical journals. Thirteen papers submitted or in preparation, as well as 73 editorials/reviews/book chapters, all in English.
Delegate for the Faculty programme “LeKA” during 2005, a programme for future leadership of research projects and groups.
Professor of Clinical Cardiovascular Research , 2008. I was promoted after an approved application to the Dean of the Faculty of Medicine. During 2008 I have replaced the previous
Head of the research group for cardiovascular research in Internal Medicine and I am now the Head (see link: http://www.med.lu.se/klinvetmalmo/forskning/hjaert_och_kaerlsjukdomar/internmedicin)
Staff-member of the Department of Community Health Sciences , University of Lund,
Sweden, 1987-1997 (clinical assistant, lecturer of Family Medicine and Social Medicine in undergraduate and postgraduate training; 50-60 hours yearly during most years). Clinical work at the Dalby Health Centre 1985-1996. Senior lecturer ("t.f. högskolelektor") 6 months

in Family medicine at the Faculty of Medicine, Lund, 1995. I am the Head of Department of
History of Medicine , University of Lund, Sweden, since 1996- .
Associate professor ("docent") and senior lecturer ("universitetslektor") of cardiovascular medicine at the Division of Clinical Research, Department of Internal Medicine ,
University Hospital, Malmö, Sweden, 1997-2008 . Clinical work at the Clinical Preventive
Medicine unit of the Department, mostly with patients referred or screened for cardiovascular risk factors. Promoted to senior consultant (Swedish: “överläkare”) in September 2008. In addition I am also the Head of our research Group in 2008 (see above).
During 2009 I have been appointed as the coordinator of a national programme for excellence in Strategic Research dedicated to epidemiology, leading the collaboration between Lund and Uppsala universities ( www.med.lu.se/epihealth ). This is supported directly by the Swedish Governement.
2. Memberships and appointments
Member of the Swedish Medical Association, 1984-.
Member of the Swedish Association for General Medicine (SFAM) , 1990 (steering committee 1995-1998).
Member of the Swedish Hypertension Society , 1987 (steering committee 1993-2005,
President 1999-2001).
Member of the European Society of Hypertension , 1992. (ESH Council member 2006-)
Member of the Nordic Association for Clinical Haemoreology , 1988 (steering committe
1993-1998).
Member of the Swedish Society for Diabetology , 1992 (steering committee 1994-2003, secretary 1994-99). National Diabetes Register outdata committee 2001-
Member of the Hypertension in Diabetes Study Group of the EASD , 1995 (steering committee 1995-2001, 2002-).
Member of the Hypertension in Diabetes Working Group of the ESH , 2002 (president, steering committee 2002-).
Member of the European Group on Insulin Resistance , 1996 (steering committe 2001-
2004).
Member of a working subcommittee of the Swedish Council for Planning and
Coordination of Research (FRN) , 1996-1999, focusing on self-rated health and the individual.
Member of the EU strategic research group (DIAMAP) for diabetes research , 2008.
2

Member of a committee on the evaluation of smoking cessation programmes of the
Swedish Council on Technology Assessment in Health Care (SBU) , 1995-1998. Coauthor of the publication on methods for smoking cessation in 1998 (SBU-series 138).
Member of the International Editorial Boards of the European Journal of Cardiovascular
Prevention and Rehabilitation , 2006-, and Journal of Hypertension 2002-2006.
3. Guest researcher
1. University of Uppsala , Sweden (Professor HO Lithell, Department of Geriatrics), 1992-
1993.
2. University and Middlesex School of Medicine, London (Professor JS Yudkin,
Department of Medicine, Whittington hospital), 1993.
3. Guest lecturer at the Medical Faculty, University of Greifswald , Germany, 1995, 1997.
4. Karolinska Institute , Stockholm, Sweden (Professor Ulf de Faire, Division of
Cardiovascular research, Department of Internal medicine, and Ingvar Krakau, associate professor, Department of Family medicine), 1997-2001.
5. University of Aarhus, Department of Family medicine, Aarhus, Denmark (Professor
Torsten Lauritzen), 1999-2002 (Ebeltoft project, guest researcher).
6. University of Umeå , Department of Medicine (Professor Birgitta Stegmayr) 2005-
(MONICA-project, guest researcher)
4. Clinical experience
Basic clincial training in Kalmar (hospital care), and Nybro and Emmaboda (primary health care) (1979-85). Experience as surgeon 4 months in Eksjö (1977). More than 12 years of clinical work as a specialist in general medicine at the Dalby Health Centre, during 1985-
1996. I was responsible for the alcohol policlinic at the health centre during the period. Parttime consultant for the local administration of sick-leave and health insurance, etc.
("Försäkringskassan"). During the recent 20 years I have regularly worked in primary health care as a GP for 2-3 weeks annually during summer vacations (Löttorp, Borgholm, Brösarp,
Tomelilla, Smålandsstenar) to keep up clinical skills in general medicine/family medicine.
5. Teaching experiences and qualifications
3

a. Formal pedagogic/teaching training: a week-long course for becoming associate professor in 1994, organised by the Faculty of Medicine, University of Lund, Sweden. Two-days course on Problem-Based Learning, University of Lund, 2002. One day of obligatory training for tutors at the Faculty of Medicine on 31 st January 2005. b. Administration of teaching: main organiser of nine postgraduate courses ("SK-kurser"), and the week-long ESH Summer School in Ystad 2003 (for 50 European doctors). Coadministrator of courses on the Metabolic syndrome for Italian physician in 2005-2006, at the
University Hospital, Malmö. c. Production of teaching materials: writer of several short summaries for medical students.
Referee and introducer for the translation of a Norwegian textbook on general medicine for medical students (Aaaras, et. al. Allmänmedicin i teori och praktik . Studentlitteratur. Lund,
1994). Author of a chapter on "Hypertension in Diabetes" in a medical textbook (reference
C:8). Author of a chapter about prevention in primary health care for a textbook on cardiovascular medicine (angiology) for medical students (Studentlitteratur AB, 2000).
Editor-in-chief of a textbook on the “The Metabolic syndrome – background and treatment”
(Studentlitteratur AB, 2006), based on the proceedings of a national meeting in Jönköping,
2005, when I was the main organiser. Author of two chapters in a textbook on obesity in
2007 (Eds. AK Lindros, S Rössner; Fetma.
Studentlitteratur AB), a chapter on “Hypertension in Diabetes” for the ESH Text-book on Hypertension in 2008, and a chapter on cardiovascular prevention (Studentlitteratur AB, 2009). d. Teaching experience for medical students: since 1987 (first as clinical assistant, thereafter as senior lecturer; mean: 10-20 hours/year), for nursing students 1981-1994 (mean: 10-15 hours/year), and for students of occupational therapy 1996-1998 (mean 6 hours/year). Focus on teaching for medical students in their fifth year of education. I was the main lecturer in social medicine/community medicine at the Department of Community health sciences,
Lund, 1990-1999, and at the Department of Community Medicine, Malmö, 2000. For many years I have been the only lecturer in social medicine in Lund, introducing the topic "Social causation of disease" for medical students. I have been co-organiser of a inter-diciplinary course on ”Humanistics and medicine” , in 2001, as appointed by the Faculty of Medicine,
Lund. In 2004-2009, I have been teaching about the Metabolic syndrome (first year) and hypertension, lipids, metabolic syndrome (third year) of studies in medicine. e. Post-graduate teaching experience: for specialists in general medicine and internal medicine since 1989 (mean 20-30 hours/year). Responsible for post-graduate week-long courses (SK-kurser; n= 9) since 1992, concerning hypertension, diabetes, social medicine,
4

prevention, and other topics in general medicine. Clinical lecturer ("t.f. högskolelektor") in general medicine for 6 months in 1995. Organiser of several national and international medical meetings 1992-2006, including activites in the Organising Committee for the
National Cardiovascular Spring Meeting (responsible for symposia, seminars 2000-2006). f. Clinical teaching tutorship: in primary health care at the Dalby health centre, for individual students 1988-1996, during their 5th year of medical education. g. Popularisation of science: participating with lectures and in panel debates at annual conferences organised by the Swedish Council for Planning and Coordination of Research
(FRN) 1996-1999 ( "Populärvetenskaplig tema-dag" på Norra Latin, Stockholm). Organiser of conferences for the same organisation. Lecturer on ”History of the University of Lund” at official meetings and courses organised by the university, 2000-2004.
During November 2008 I organised three major open meeting for the public with the aim to give example of research based on the population screenings in Malmö 1974-2008. This was supported by the Faculty of Medicine in Lund-Malmö and attended by 300 lay people.
6. Scientific competence a. Scientific papers in peer-reviewed journals: a total of 149 English papers have been published or accepted for publication, as well as 63 English reviews that have also been published or accepted. In all, 13 manuscripts are in different stages of progress to be submitted or revised. Additionally more than 150 papers have been published in Swedish, mostly in peer-reviewed journals (AllmänMedicin, DiabetologNytt, Läkartidningen, Nordisk
Medicin, Socialmedicinsk Tidskrift, etc.). b. Scientific cooperation: I have organised scientific multi-centre studies (J Internal Med
1996; 240:189-94) and worked jointly with several national and international research groups. I have worked in a task force group for the implementation of a National Programme of Quality Assurance for the Secondary Prevention of Coronary Heart disease (reference
A:56, A:63) 1998-2003. The aim was to improve the control of cardiovascular risk factors in patient post-myocardial infarction, PTCA or CABG. This project was jointly run by the
Swedish Association for General Medicine, the Swedish Cardiology Society, and supported by the Swedish Board of Health and Wellfare ("Socialstyrelsen").
5

During 2000-2009 I have been working together with a task force for evaluation and publication of data from the
National Diabetes Register (NDR)
of Sweden, resulting in about
15 original publications. This is work to improve the quality of diabetes care on a national scale. I presently represent these aspects of quality in diabetes care with the EU Task Force
(DIAMAP) for shaping future research strategies. (Reference: Halban PA, Smith U,
Diabetologia . 2008 Oct;51:1765-7). c. Scientific support: I have belonged to various research groups receiving large financial support, previously together with Professor Göran Berglund at the Department of Clinical
Sciences Medicine at the University Hospital in Malmö. For my clinical studies in Dalby/Lund
I have received, alone or together with other colleagues, about 800.000 SEK as external scientific support throughout the years. I was grant holder for a post-doctorial scholarship of the Swedish Medical Association (12 months) in 1992-94. In Malmö I have received a total of more than 6.000.000 SEK during the period 1998-2009 as research grants, e.g. from the
Heart and Lung Foundation (800.000 SEK) in 2004-2006, as well as from the Research
Council of Sweden 2008-2010 (grant: 2007-3533). In addition I belong to scientific networks with EU-funding for research, such as EGIR and EPIC-Interact, with total grants of more than 100.000 Euros during 2002-2008. d. Scientific referee for: the journals Circulation, Journal of Hypertension, Blood Pressure,
Scandinavian Journal of Primary Health Care, Scandinavian Journal of Social Medicine,
Journal of Internal Medicine, Diabetologia, Läkartidningen (in Swedish). In all, about 250 requests so far. I have also been reviewer for grant applications to the research councils of
Denmark, Norway, Czech Republic, Serbia-Montenegro, South-Africa (MRC) and the UK during 2002-2008. e. Scientific principal tutor for primary health care physician Rickard Ekesbo , Dalby
( ”Chronic infection in primary health care – cardiovascular and gastrointestinal aspects” ,
Dissertation approved 26 th September 2003) and specialist in internal medicine Bertil Öhlin
( Stress and cardiovascular disease , Dissertation approved 8 th
June 2007) Department of
Medicine, Malmö. Furthermore, I was the principal tutor in history of medicine for researcher
Inga Nilsson ( History of the medical documentation in Sweden, 1700-2000 ), Dissertation approved 1 st February, 2008. Ulla Pettersson ( Screening for cardiovascular risk and diabetes in primary health care. The Söderåkra Risk Factor Screening Study ) (29 th
April
2009), University of Linköping, and for Gunilla Journath (Risk factor control in treated hypertensives and patients with diabetes in primary health care, Dissertation 29 th May 2009),
Karolinska Institute, Stockholm.
6

I was co-tutor for a thesis in History of medicine 1999 ( Caroline Arsini , Lund, PhD, with dissertation in February 1999 entitled: "Health in Medieval Lund" ). I have also been co-tutor for Marie Ekberg-Aronsson ( “Smoking and airway disorders in an urban population – special references to gender and socio-economic status” . Dissertation aproved 24 th
November 2006), Rasmus Borgqvist ( “Coronary Heart Disease and erectile dysfunction”,
Dissertation aproved 2 nd
June 2007), and Gordana Tasevska-Dinevska (“ Gender aspects on heart failure”, Dissertation approved 18 th December 2008).
I am currently principal tutor for Margret Leosdottir (Glucose intolerance/diabetes and myocardial dysfunction) with approved half-way control 100512, for Lisa Bellinetto-Ford
(vascular ageing), Nils Hansson (history of medicine) and Tomas Gustafsson (history of medicine), all four at Lund university. In addition I am also the main tutor for Payam Khalili
(Örebro University) I am also co-tutor for Rose-Marie Hofvander , Primary Health Care,
Lund.
In May 2005, I concluded a training seminar series of the Faculty of Medicine, Lund, for future leaders/tutors in academic research (LeKA-programme). f. Scientific evaluation of theses. At altogether nineteen occasions I have been member of the faculty-appointed board for evaluation of theses ("betygsnämnd"). I have eight times been appointed as principal (first) opponent of a thesis (by Karolinska Institute ,
Stockholm, 1998 (for Jonas Tovi), by the Medical Faculty, University of Gothenburg , 2001
(for Ludger Grote), by the Medical Faculty,
University of Oslo
, 2001 (for Aud Høieggen), by the Medical Faculty,
University of Copenhagen
, 2001 (for Thomas Drivsholm), and by the
Karolinska Institute , Stockholm, 2004 (for Constanze Leineweber), and in 2005 (for Gunnar
Kaati, Karin Leander) and in 2008 (for Anna Karin Edstedt-Bonamys).
7. Administrative experience a. Responsible for the Clinical Research Laboratory in Dalby 1994-1995 (staff: 3 members). b. Head, Department for History of Medicine, Medical Faculty, Lund, 1996- . In this position I have organised annual seminars and debates, as well as participation in national and international meetings. I was recognised at the national medical meeting (“Riksstämman”) in
7

1999 for best presentation in History of Medicine. Several publications have been written
1995-2008, see the Annual reports series. I am responsible for a budget and for staff (one secretary) and one PhD student (Nils Hansson). c. I have been the main organiser of 12 large-scale national and 2 large-scale international medical meetings during the past fifteen years. I acted as chairman of the organising committee, of a Berzelius-symposium entitled "Social causation of disease - biological mechanisms" , 10-12th May 2000, initiated by the Swedish Association for General Medicine.
I was one of the co-organisers of Berzelius-symposium on ”Sleep and restitution – implications for health ” in August, 2002. I was chairman of the Organising Committee for the
Berzelius symposium “Developmental origins of adult disease – focus on stress response, glucose metabolism, and cardiovascular risk” on 20-22 nd
September 2006, in collaboration with the Swedish Society of Medicine and the Royal Society of Medicine, UK. This symposium was published as a Mini-symposium included in Journal of Internal Medicine in
May 2007. d. On behalf of the Swedish Council for Planning and Coordination of Research (FRN), I have organised a joint East-West scientific meeting on "Self-rated health in Europe" in
Prague, Czech Republic, September, 1998. This conference was documented in a book
(Proceedings) in 2000. e. Project manager of a large multi-centre study on smoking cessation in primary health care
(J Internal Med 1996; 240:189-94). f. Co-organiser of a large-scale research project on lifestyle, insulin resistance and cardiovascular disease (The Malmö Preventive Project) at the Department of Clinical Medical
Research at the University Hospital in Malmö, starting in November 1998. During 2002-2006 a total of 18,200 subjects have been re-examined in a large-scale project that I am responsible for (grants from the Heart- and Lung Foundation). At present we are conducting a similar re-screening of 4000 subjects within the Malmö Diet Cancer Cardiovascular Arm aiming at long-term investigations of the Early Vascular Ageing (EVA) syndrome (Research
Council support 2008-2010). (Nilsson PM, Lurbe E, Laurent S. The early life origins of vascular ageing and cardiovascular risk: the EVA syndrome. Review.
J Hypertens
2008;
26:1049-1057). g. Leading positions of scientific organisations: e.g. president (Swedish Hypertension Society
1999-2001), secretary (Swedish Association for Diabetology 1994-1999), and treasurer
8

(Hypertension in Diabetes EASD Study Group 1995-2001). In 2006 I started working for the
European Hypertension Society (ESH) as a
Council member
(reference: ESH President
Professor Stéphane Laurent, Paris, France). h. Head of Research group: I have been appointed administrative Head of the research group for internal medicine at Department of Clinical Sciences, Lund University, University
Hospital, Malmö, in May 2008. For more information see our web-page: http://www.med.lu.se/klinvetmalmo/forskning/hjaert_och_kaerlsjukdomar/internmedicin
General aspects
It is always a difficult task to be asked for self-evaluation, and I will just give some brief comments. Instead I think it is more appropriate to provide some names of persons for reference, as listed after each subheading. These persons could inform about my achievements in a more objective way as they know me from various activities.
1. Scientific merits
During almost 20 years I have been writing a large number of original papers and reviews, mostly within the field of hypertension, diabetes, cardiovascular risk, general medicine and prevention. Besides of that I have participated in several projects and publications devoted to the improvement of health care for patients with diabetes and/or ischaemic heart disease. A new interest that I have tried to develop over the last 10 years is the concept of early biological ageing as a model for how social and lifestyle factors might influence biological systems and increase the risk for early morbidity and mortality. As part of an ongoing project in Malmö we are going to use new markers for this model, such as pulse wave velocity
(PWV) and telomere length after DNA extraction. I have been honoured to be able to work as a guest researcher together with the late professor Hans Lithell, Uppsala, on projects related to insulin resistance, blood pressure regulation, and cardiovascular risk factor screening. In later years I have also focused on early life factors for fetal and post-natal programming of cardiovascular disease. In preventive medicine I have published on childhood accident prevention, smoking cessation, and the implementation of a healthy lifestyle at the workplace in a randomised clinical trial. As science is an important part of my life, I hope that I have contributed somewhat within my various fields of research.
9

I have received research grants form the Heart- and Lung Foundation 2007-2008 (HLF),
Vetenskapsrådet 2008-2010 (Swedish Research Council), as well as local and regional grants. In addition I am a co-applicant for EU grants (EGIR, EPIC-Interact). During 2008 I have joined the team of Professor Leif Groop for the EU application of IMI within the
SUMMIT consortium. We have now received a grant worth 14 million Euros, and the project is targeted for macrovascular complications in diabetes.
Not to be forgotten, I have also published a number of papers in Swedish related to the
History of medicine, as part of my responsibilities as Head of department.
References: Dean of the Faculty of Medicine, Lund University Bo Ahrén
( bo.ahren@med.lu.se
), Professor Leif Groop ( leif.groop@med.lu.se
), professor Lennart
Råstam ( lennart.rastam@med.lu.se
) and professor of general medicine Jan Sundquist
( jan.sundquist@med.lu.se
)
2. Teaching merits
I have been teaching on a regular basis ever since I started teaching at the local school for nurses in Kalmar in the early 80-ies. Since then I have annually had about 10-20 teaching sessions for undergraduate health care students, and about the same amount for postgraduate training courses or seminars for physicians. Teaching has always been dear to me and this has also resulted in tutorship for a number of about 20 medical students writing their papers in clinical medicine or history of medicine, some of them have later been possible to publish. I also teach regularly abroad, most often in Eastern and Central Europe as part of collaboration for cardiovascular prevention in countries such as the Ukraine, Byelarussia,
Lithuania, Latvia, Estonia, Poland, and the Czech Republic. My formal teaching merits have made it possible for me to become a tutor of scientific thesis (9 thesis already approved; written by Rickard Ekesbo 2003, Caroline Arcini 1999, Marie Ekberg-Aronsson 2006,
Rasmus Borgqvist 2007, Bertil Öhlin 2007, Inga Nilsson 2008, Gordana Tasevsjka 2008,
Ulla Petersson 2009, and Gunilla Journath 2009) and five more underway. Teaching is an integrated part of my work position as university teacher (senior lecturer) since 1997 onwards. All together I currently give about 50 major lectures a year in Sweden or abroad.
My teaching skills have also been used for writing teaching materials av various kind, including editing books.
10

References: Senior university lecturer Bodil Ohlsson ( bodil.ohlsson@med.lu.se
) responsible for undergraduate teaching in clinical medicine at the University Hospital, Malmö, Professor
Stefan Lindgren ( stefan.lindgren@med.lu.se
) responsible for planning of teaching at the
Faculty during 2001-2005, and Associate Professor Martin Garwicz
( Martin.Garwicz@med.lu.se
), responsible for undergraduate teaching for medical students in
Lund.
3. Clinical merits
Being a physician since 25 years has made it possible for me to get a wide clinical experience, first as a general practitioner at the primary health centre in Dalby 1987-1996, and after that involved in clinical work mostly with cardiovascular risk patients in Malmö during 1997-2006. Without clinical skills in cardiovascular medicine and prevention, based on consultations with many 1000´s of patients, it would not have been possible for me to act as project leader in various projects and as one of the organisers behind the workshop for prevention of atherosclerotic diseases, as organised by the Swedish Medical Product
Agency in 2005, published in 2006. This is a national guidelines document for all Swedish physicians working with cardiovascular prevention. Every year I still do clinical work for 2-3 weeks in the summer at primary health care centres, to keep up clinical skills.
References: Dr. Olof Hedener ( olof.hedener@skane.se).at
the Brösarp Primary Health Care centre, and Helena Bergström, Kalmar County Council administration ( helenab@ltkalmar.se
)
3. Administrative merits
I have been involved with administrative work both to run departments and to lead singlecentre or multi-centre projects. At present I am responsible for research budgets for largescale projects in Malmö, but also for running the Department of History of Medicine, Lund
University. During 2005 I participated in an educational programme for new research group leaders of the Faculty of Medicine, Lund University (the so called LeKA programme –see certificate). Administration has been a challenge that I have faced more and more during recent years, and now I have been appointed as senior research group leader at the
Department of Clinical Sciences, Lund University, University Hospital, Malmö (see link: http://www.med.lu.se/klinvetmalmo/forskning/hjaert_och_kaerlsjukdomar/internmedicin ).
11

In 2009 I have been the coordinator for a very large researcg grant application to the
Swedish Research Council for 65 million SEK called Health in Epidemiology (EpiHealth), and building upon collaboration with several research groups in Lund, Malmö and Uppsala. Final decision is awaited on June 15 th 2009.
References: Professor Bo Ahrén ( bo.ahren@med.lu.se
) Dean of the Faculty of Medicine,
Lund University, Lennart Råstam (lennart.rastam@med.lu.seand Secretary Märta Granbohm
( marta.granbohm@med.lu.se
) at the Department of History of Medicine, Lund University.
5. Other merits
During the last decade I have organised several large-scale seminars, Berzelius symposia, teaching courses etc., and this has been very enjoyable for me as I have had good coworkers and the result has most often been very rewarding. As part of the writing committee for the National Diabetes Register (NDR) of Sweden I have worked for a couple of years together with skilful colleagues dedicated to improve the standard of diabetes care following the St. Vincent Declaration for diabetes care . We have been able to show improving trends in risk factor control (HbA
1c
, blood pressure, lipids) based on data since 1996 in currently about half (220,000 subjects) of all patients with diabetes in Sweden. This has been very interesting and has given me the opportunity to get in closer contacts with patients´ organisations.
In the military service I was appointed lieutenant and chief of a Field Dressing Station at the level of an infantry battalion during 1988 to 2000.
References: Dr. Soffia Gudbjörnsdottir ( soffia.gudbjörnsdottir@medic.gu.se
) for the NDR, and Associate Professor Martin Ridderstråle ( martin.ridderstrale@med.lu.se
) for organisation of teaching seminars in Malmö.
Conclusion
I have devoted my working life to clinical medicine and clinical research as well as teaching, and thereby I have been very privileged indeed. Not everything has ended the way it was planned from the beginning and I must admit that without the support of my wife Ulla-Gerd and my family this achievement would not have been possible at all. Once I wanted to become a surgeon or a neurologist, but general practice soon impressed me with fascinating
12

consultations involving so many people with a wide range of human problems. Other people will have to judge upon my merits, but I have travelled a path that I would not hesitate to walk again if needed. Sometimes I think for myself that I have been lucky to hopefully be able to help many more people indirectly, through teaching of students and physicians, writing guidelines, promoting of prevention, etc, than directly during everyday clinical contacts.
However, without these human meetings and consultations my working life would have been dull.
Clinical experience
- specialist in general medicine/family medicine for 24 years with at least 11 years of work as a GP at the Health Centre in Dalby, and thereafter regular work for 2-3 weeks annually in primary health care at various health centres in Southern Sweden
- everyday clinical work with cardiovascular risk patients at the Clinical Research Unit
Medicine (CRUM) at the Department of Internal Medicine, University Hospital, Malmö, at present as senior consultant (15% of full-time employment) (“överläkare”).
Scientific experience
- main author or co-author of a total of 175 original papers (published or accepted for publications), with 40 of them during 2008. In addition I have authored more than 60 reviews or chapters in Text-book of medicine, as well as more than 100 papers in
Swedish in peer-reviewed journals.
- active member of scientific networks at the local, regional, national or international levels. Co-applicant of research large project proposals with the EU (EGIR, EPIC)
- promoted to Professor of Clincial Cardiovascular Research, Lund University, in 2008
Pedagogical experiences
- main tutor for 5 PhD students with accepted theses 2003-2009. In addition I am at present the main tutor for 2 other PhD students as well as a co-tutor for three more
- a long-time experience in teaching undergraduate medical students and nurse students, as well as long-standing activities in post-graduate teaching and training, both on the regional, national and international level (e.g. as a faculty member of the
European Hypertension Society Summer School since seven years).
- Author of a long series of materials and text-book chapter for educational activities
Administrative experiences
13

- Head of Department of History of Medicine, Lund University since 1996, with independent budget responsibilities
- Head of the research group for cardiovascular research in internal medicine at my
Department of Clinical sciences, Lund university, University Hospital, Malmö
- responsible for large grants and research support from the Swedish Research
Council, from the Heart and Lung Foundation, and from the EU in international collaborative projects
14

On Medline/PubMed, papers are found under either “Nilsson P” or “Nilsson PM”
2.
1987 - 1990
1. * Nilsson P, Lindholm L, Scherstén B, Horn R, Melander A, Hesch RD.
Atrial natriuretic peptide and blood pressure in a geographically defined population.
Lancet 1987; 2:883-5.
Nilsson P, Lindholm L, Winther K, Scherstén, B Hesch R. High urinary cAMP in hypertensives despite careful drug treatment - an epidemiological study from the Dalby population.
J Intern Med 1990; 228:603-9 .
3. Nilsson P, Lindholm L, Scherstén B. Hyperinsulinemia and other metabolic disturbances in well-controlled hypertensive men and women: an epidemiological study of the Dalby population. J Hypertens 1990; 8:953-9 .
1991
4. Nilsson P, Lindholm L, Karlberg B, Scherstén B. Extracted atrial natriuretic peptide not elevated in treated hypertensives.
J Hypertens
5.
1991; 9:481-2 .
Nilsson P. Metabolic disturbances in primary hypertension. Special focus on non-pharmacological treatment of hyperinsulinemia.
Studentlitteratur, Lund, 1991 .
Thesis .
8.
7.
1992
6. * Nilsson P, Lindholm L, Scherstén B. Lifestyle changes improves insulin resistance in hyperinsulinemic subjects. A one-year intervention study of hypertensives and normotensives in Dalby. J Hypertens 1992; 10:1071-8 .
Nilsson PM, Hagander BM, Lindholm LH, Scherstén B. Effects on glucose metabolism but not on cholesterol remain when intensity of non-pharmacological treatment is reduced. Scand J Nutr 1992; 36:102-5 .
Nilsson P, Lindholm L, Scherstén B. Decrease of plasma fibrinogen by non-pharmacological treatment - a one-year study. In: Ernst E, Koenig W, Lowe
GDO, Meade TW (Eds.), Fibrinogen: A "new" cardiovascular risk factor.
(Chapter). Blackwell-MZV, Wien, 1992.
1993
9. Nilsson P, Kandell-Collén A, Lindholm LH, Scherstén B. The care of hypertensives in Dalby - Organization and health economic aspects.
J Hum Hypertens 1993; 7:551-4.
15

10. * Nilsson P, Andersson DKG, Andersson P-E, Schwan Å, Östlind B, Malmborg R,
Lithell H, Andersson OK. Cardiovascular risk factors in treated hypertensives - a nation-wide, cross-sectional study in Sweden. J Intern Med 1993; 233:239-45 .
1994
11. Nilsson P, Östergren P-O, Lindholm L, Scherstén B. Can social class differentials in hypertension be explained by the "general susceptibility" hypothesis? Soc Sci Med 1994; 38:1235-42.
12. Nilsson P, Lindholm LH, Scherstén B. No additional beneficial effects in hypertensives well cared for when their medication is changed to diltiazem - a one-year, randomized pilot study. High Blood Pressure & Cardiovascular
Prevention 1994; 3:57-63.
13. Lind H, Nilsson P, Holthuis N, Lindholm L. Insulin, lipoprotein (a) and other cardiovascular risk factors in 40-year-old Swedish men. - A population-based study. Scand J Clin Lab Invest 1994; 54:177-83 .
14. Nilsson P, Lind L, Andersson P-E, Hänni A, Berne C, Baron J, Lithell H.
On the use of ambulatory blood pressure recordings and insulin sensitivity in support of the insulin-hypertension hypothesis. J Hypertens 1994; 12:965-9.
1995
15. Nilsson P, Lind L, Pollare T, Berne C, Lithell H. Increased level of glycosylated hemoglobin A1C, but not impaired insulin sensitivity, found in hypertensive and normotensive smokers compared to non-smokers.
Metabolism 1995; 44:557-61.
16. Nilsson P, Möller L, Solstad K. Adverse effects of psychosocial stress on gonadal function and insulin levels in middle-aged males. J Internal Med 1995; 237:479-86.
17. Nilsson P, Schwan Å. Independent association between fasting plasma insulin and ambulatory blood pressure in 50-year old females. Blood Pressure 1995; 4:283-6.
1996
18. Nilsson P, Lindholm L, Hedner T. The Diltiazem Different Doses study - (DDD).
A dose-response study of once-daily diltiazem therapy in hypertension. J Cardiovasc
Pharmacol 1996; 27:469-75 .
19. Nilsson P, Lindholm LH, Scherstén B. Sex differences in cardiovascular risk factors independent of abdominal fat distribution. Scand J Prim Health Care 1996;
14:177-83 .
20. * Nilsson P, Lundgren H, Söderström M, Fagerström K-O, Nilsson-Ehle P. Effects of smoking cessation on insulin and cardiovascular risk factors - a controlled study of 4 months duration. J Internal Med 1996; 240:189-94 .
21. Nyström F, Nilsson P, Olsson AG, Karlberg BE, Öhman KP. A population study of neuropeptide Y: correlations with components of the metabolic syndrome.
Pressure 1996; 5:349-53 .
Blood
16

22. Nilsson P. Premature ageing - the link between psychosocial risk factors and disease? Med Hypotheses 1996; 47:39-42.
1997
23. Isacsson Å, Fredriksen SG, Nilsson P, Hedenbro JL. Quality of life after gastroplasty is normal: a controlled study. Eur J Surg 1997; 163:181-6 .
24. Hultqvist M, Hegbrant J, Nilsson-Thorell C, Lindholm T, Nilsson P, Lindén T,
Hultkvist-Bengtsson U. Plasma concentrations of vitamin C, vitamin E and/or malondialdehyde as markers of oxygen free radical production during hemodialysis. Clinical Nephrology 1997; 47:37-46.
25. Eliasson M, Nilsson P, Jansson J-H. Increased levels of tissue plasminogen activator antigen in essential hypertension - A population-based study in Sweden.
J Hypertens 1997; 15:349-56.
26. Nilsson P, Kandell-Collén A, Andersson I. Blood pressure and metabolic factors in relation to chronic pain. Blood Pressure 1997; 6:294-8 .
27. * Nilsson P, Möller L, Köster A, Hollnagel H. Social and biological predictors of early menopause - a model for premature ageing. J Internal Med 1997; 242:299-305.
28. * Nilsson P, Söderström M, Ericson A, Östergren P-O, Allebeck P. Low birth weight is associated with elevated systolic blood pressure - a study of 149,378 male
Swedish military conscripts. J Hypertens 1997; 15:1627-31.
1998
29. Hagström B, Nyberg P, Nilsson P. Asthma in adult life - is there an association with low birth weight? Scand J Prim Health Care 1998;16:117-20.
30. Nilsson P, Johansson S-E, Sundqvist J. Low educational status is a risk factor for mortality among diabetic people Diabetic Medicine 1998; 15:213-9.
31. Nilsson P, Gullberg G, Ekesbo R, von Schenck H, Gustafson L. No impaired cognitive function in treated patients with mild-moderate hypertension, compared to matched normotensive controls.
Blood Pressure 1998; 7:209-13 .
1999
32. Larsson D, Lager I, Nilsson P. Social situation and quality of life in diabetes mellitus - relation to metabolic control. Scand J Public Health 1999; 2:101-5.
33. Nilsson P, Abelin J, Katzman P, Thulin T. Once-daily doses of nifedipine and felodipine in essential hypertension - evaluation by 24-h ambulatory blood pressure monitoring. Arterial Hypertens (Poland) 1999; 3:9-14.
34. Nilsson P. Increased weight and blood pressure in adolescent male offspring to mothers with pre-pregnancy diabetes - a genetic link? J Hum Hypertens 1999;
13:793-5.
17

35. Nilsson P, Lind L, Pollare T, Berne C, Lithell H. Differences in insulin sensitivity and risk factors due to gender and menopause in hypertensives. J Hum Hypertens
2000;14:51-56.
36. * Berglund G, Nilsson P, Hedblad B, Eriksson K-F, Nilsson J-Å, Lindgärde F,
Kristensson H. Long-term outcome of the Malmö Preventive Project. Total mortality and cardiovascular morbidity. J Intern Med 2000;244:19-29.
37. Hedblad B, Nilsson P, Janzon L, Berglund G. Relation between insulin resistance and carotid intima-media thickness and stenosis in non-diabetic subjects.Results from a cross-sectional study in Malmö, Sweden. Diabetic Medicine 2000;17:299-307.
38. Ekesbo R, Nilsson P, Lindholm LH, Persson K, Wadström T. Combined seropositivity for H. pylori and C. pneumoniae is associated with age, obesity and social factors. J Cardiovasc Risk 2000;7:191-5.
39. Svartvik L, Lidfeldt J, Nerbrandt C, Samsioe G, Scherstén B, Nilsson P.
Dyslipidaemia and impaired wellbeing in middle-aged women reporting low Sense of
Coherence. The Women´s Health in the Lund Area (WHLA) Study. Scand J Prim
Health Care 2000;18:177-182.
2001
40. * Nilsson P, Klasson E-B, Nyberg P. Lifestyle intervention at the worksite - reduction of cardiovascular risk factors and cortisol in a randomized study. Scand J Work
Environ Health 2001;27:57-62.
41. Nilsson P, Nyberg P, Östergren P-O. Susceptibility to a psychological stress test in young males is associated with low birth weight. Int J Epidemiol 2001;30:75-80.
42. Vides H, Nilsson P, Sarapuu V, Poodar T, Isacsson Å, Scherstén B. Metabolic control and living conditions for diabetes patients in Viljandi, Estonia - A population-based study. Eur J Public Health 2001;11:60-4.
43. Nilsson P, Nilsson J-Å, Hedblad B, Berglund G. Sleep disturbances interacts with elevated pulse rate for the prediction of mortality - Consequences of mental strain?
J Internal Med 2001;250:521-9.
2002
44. Hedblad B, Nilsson P, Engström G, Janzon L, Berglund G. Insulin resistance in nondiabetic subjects is associated with increased incidence of myocardial infarction and death. Diabetic Medicine 2002;19:470-5.
45. Norinder A, Persson U, Nilsson P, Nilsson J-Å, Hedblad B, Berglund B. Costs for screening, intervention and hospital treatment generated by the Malmö Preventive
Project; a large-scale community screening programme. J Internal Med
2002;251:44-52 .
18

46. Cederholm J, Nilsson PM, Anderberg CP, Fröberg L, Petersson U, for the Q-Heart
Study Group. Blood pressure and other cardiovascular risk factors among treated hypertensives in Swedish primary health care. Scand J Prim Health Care
2002;20:224-9.
47. Nilsson PM, Nilsson J-Å, Hedblad B, Berglund G, Lindgärde F. The enigma of increased mortality associated with weight-loss in middle-aged men - the Malmö
Prevention Project. J Internal Med 2002;252:70-8.
48. Jonsson S, Hedblad B, Engström G, Nilsson P, Berglund G, Janzon L. Influence of obesity on cardiovascular risk. Twenty-three year follow-up of 22 025 men from an urban Swedish population. Int J Obes Relat Metab Disord 2002;26:1046-53 .
49. Nilsson TK, Spence JD, Nilsson PM, Eliasson M, Jansson J-H, Boman K.
Quantitative measurement of carotid atherosclerosis in relation to levels of von
Willebrand factor and fibrinolytic variables in plasma – a 2-year follow-up study.
J Cardiovascular Risk 2002;9:215-21.
50. Khalili P, Nilsson PM, Nilsson J-Å, Berglund G. Smoking as a modifier of the systolic blood pressure-induced risk of cardiovascular events and mortality: a populationbased prospective study of middle-aged men. J Hypertens 2002;20:1759-64.
51. Hedblad B, Jonsson S, Nilsson P, Engström G, Berglund G, Janzon L. Obesity and myocardial infarction – vulnerability related occupational level and marital status. A
23-year follow-up of an urban Swedish population. J Internal Med 2002;252:1-9.
52. Frequency of the WHO Metabolic Syndrome in European cohorts, and an alternative definition of the Insulin Resistance Syndrome. The European Group for the Study of
Insulin Resistance (EGIR). (including Nilsson P and Hedblad B for the Malmö centre).
Diabetes Metab (Paris) 2002; 28:364-76.
53. Nilsson PM, Hedblad B. Prevalence of the Metabolic Syndrome: Impact on cardiovascular risk epidemiology – A populationbased study from Malmö, Sweden.
Heart Drug 2002;2:273-8 .
2003
54. * Nilsson PM, Hedblad B, Eriksson K-F, Berglund G. Hyperinsulinaemia as a long-term predictor of death and ischaemic heart disease in nondiabetic men: The Malmö
Preventive Project. J Internal Med 2003;253;136-45.
55. * Nilsson PM, Gudbjörnsdottir S, Eliasson B, and Cederholm J, for the Steering
Committee of the National Diabetes Register, Sweden . Hypertension in diabetes – trends in control and relation to macrovascular morbidity in repeated national surveys from Sweden. J Hum Hypertens 2003;17:37-44 .
56. Nilsson PM, Brandström H, Lingfors H, Israelsson B, Hedbäck B, Sjöberg G, Erhardt
L. Gender differences in secondary prevention of coronary heart disease: reasons to worry or not?. Scand J Prim Health Care 2003;21:37-42.
57. * Gudbjörnsdottir S, Cederholm J, Nilsson PM, Eliasson B, for the Steering Committee of the National Diabetes Register. The National Diabetes Register in Sweden. An
19

implementation of the St. Vincent Declaration for Quality Improvement in Diabetes
Care. Diabetes Care 2003;26:1270-6.
58. Nilsson PM, Nilsson E, Svanberg L, Samsiö G. Longevity after early surgical menopause – what is the long-term effect of a permanent cessation of reproductive function and female sex hormone loss? Eur J Gynecol Obstetr 2003;110:63-5.
59. Engström G, Hedblad B, Nilsson P, Wollmer P, Berglund G, Janzon L. Lung function, insulin resistance and incidence of cardiovascular disease: a longitudinal cohort study. J Internal Med 2003;253:574-81.
60. Håkansson C, Svartvik L, Lidfeldt J, Nerbrandt C, Samsioe G, Scherstén B, and
Nilsson PM. Well-beingand occupational roles among middle-aged women. Scand J
Occupational Therapy 2003;10:99-106.
61. * Nilsson P, Engberg M, Nilsson J-Å, Lauritzen T. Social and marital predictors of early ageing - insights from the Ebeltoft Health Study. Scand J Public Health
2003;31:255-60.
2004
62. * Nilsson PM, Nilsson J-Å, and Berglund G. Family burden of cardiovascular mortality – risk implications for offspring in a national register linkage study based upon the
Malmö Preventive Project . J Internal Med 2004;255:229-35.
63. Stagmo M, Israelsson B, Brandström H, Hedbäck B, Lingfors H, Nilsson P, Erhardt L.
The Swedish National Programme for quality control of secondary prevention of coronary heart disease – results after one year. Eur J Cardiovasc Prev Rehab
2004;11:18-24.
64. Nilsson PM, Theobald H, Journath G, Fritz T. Gender differences in risk factor control and treatment profile in diabetes: a study in 229 Swedish primary health care centres.
Scand J Prim Health Care 2004; 22:27-31.
65. Nilsson PM, Nilsson JÅ, Östergren PO, Rasmussen F. Fetal growth predicts stress susceptibility in young adulthood independent of parental social class: Cohort study of
161,991 Swedish male conscripts. J Epidemiol Community Health 2004; 58:571-3.
66. Öhlin B, Nilsson PM, Nilsson J-Å, Berglund G. Self-reported psychosocial stress predicts cardiovascular morbidity and mortality in middle-aged subjects – a long-term follow-up. Eur Heart J 2004;25:867-73 .
67. Nilsson PM, Gudbjörnsdottir S, Cederholm J, and Eliasson B, for the Steering
Committee of the Swedish National Diabetes Register. Smoking patients with diabetes exhibit higher rates of HbA
1c
and microalbuminuria than non-smokers - data from the Swedish National Diabetes Register. Diabetes and Metabolism
2004;30:261-8.
68. Sarafidis PA , Lasaridis AN, Nilsson PM, Hitoglou-Makedou AD, Pliakos CI, Kiriakos A et al.
Ambulatory blood pressure reduction after rosiglitazone treatment in patients with type 2 diabetes and hypertension correlates with insulin sensitivity increase. J
Hypertens 2004;22:1769-77.
20

69. Fagerberg B, Bondjers L, Nilsson PM. Low birth weight in combination with catch-up growth predicts the occurrence of the metabolic syndrome in men in late middle age.
The Atherosclerosis and Insulin Resistance (AIR) Study. J Internal Med 2004;256:1-
6.
70. * Nilsson PM, Rööst M, Engström G, Hedblad B, Berglund G. Incidence of diabetes in middle-aged men is related to sleep disturbances. Diabetes Care 2004;27:2464-9.
71. Holmberg AH, Johnell O, Nilsson PM, Nilsson J-Å, Berglund G, Åkesson K.
Forearm bone mineral density in 1294 middle-aged women – a strong predictor of fragility fractures. J Clin Densiometry 2004;7:419-23.
72. Leosdottir M, Nilsson P, Nilsson JA, Månsson H, Berglund G. The association between total energy intake and early mortality: data from the Malmö Diet and
Cancer Study. J Internal Med 2004;256:499-509.
2005
73. Sarafidis PA , Lasaridis AN, Nilsson PM, Hitoglou-Makedou AD, Pagkalos EM, Yovos
JG, et al.
The effect of rosiglitazone on urine albumin excretion in patients with type 2 diabetes. Am J Hypertens 2005;18:227-34.
74. Dröyvold W, Lydersen S, Midthjell K, Nilsen TIL, Nilsson PM, Nilsson J-Å, Holmen J.
Weight change and mortality: the Nord-Trøndelag Health Study. J Internal Med
75.
2005;257:338 –345.
Cederholm J, Eliasson B, Nilsson PM , Weiss L, Gudbjörnsdottir S, for the Steering
Committee of the Swedish National Diabetes Register. Microalbuminuria and risk factors in type 1 and type 2 diabetic patients. Diabetes Res Clin Pract 2005;67:258-
66.
76. Borg S, Persson U, Ödegaard K, Berglund G, Nilsson J-Å, Nilsson PM. Obesity, survival and hospital cost, findings from a screening project in Sweden. Value in
Health 2005; 8:562-71.
77. af Sillén U, Nilsson J-Å, Månsson N-O, Nilsson PM. Self-rated health in relation to age and gender – influence on mortality. Scand J Public Health 2005; 33:183-189.
78. Eliasson B, Cederholm J, Nilsson PM, Gudbjörnsdottir S, for the Steering Committee of the Swedish National Diabetes Register. The gap between guidelines and reality:
Type 2 diabetes in a national diabetes register 1996-2003. Diabetic Medicine
2005;22:1420-6.
79. Journath G, Nilsson PM, Petersson U, Paradis B-A, Theobald H, Erhardt L, for the
Hyper-Q Study Group. Hypertensive Smokers Have a Worse Cardiovascular Risk
Profile than Non-Smokers in spite of Treatment – A National Study in Sweden. Blood
Pressure 2005;14:144-50.
80. Hellénius ML, Nilsson PM, Elofsson S, Johansson J, Krakau I. Reduction of high cholesterol levels associated with younger age and longer education in a primary
21

health care programme for cardiovascular prevention . Scand J Prim Health Care
2005; 23:75-81.
81. Håkansson C, Eklund M, Lidfeldt J, Nerbrand C, Samsioe G, Nilsson PM. Well-being and occupational roles among middle-aged women. Work 2005;24:341-51.
82. Leosdottir M, Nilsson PM, Nilsson J-Å, Månsson H, Berglund G. Dietary fat intake and early mortality patterns - data from The Malmö Diet and Cancer Study. J Internal
Med 2005;258:153-65.
83. Nilsson P, Nilsson J-Å, Hedblad B, Östergren P-O, Berglund G. Social mobility, marital status and mortality risk in an adult life course perspective - the Malmö
Preventive Project. Scand J Public Health 2005; 33:412-23.
84. Ekberg-Aronsson M, Pehrsson K, Nilsson JÅ, Nilsson PM, and Löfdahl CG. Mortality in GOLD stages of COPD and its dependence on symptoms of chronic bronchitis.
Resp Dis 2005; 6: 98 [doi:10.1186/1465-9921-6-98]
85. * Nilsson PM, Cederholm J, Gudbjörnsdottir S, and Eliasson B, for the Steering
Committee of the National Diabetes Register of Sweden. Predictors of successful long-term blood pressure control in patients with diabetes – prospective data from the
National Diabetes Register (NDR) of Sweden. J Hypertens 2005;23:2305-11.
86. Sarafidis PA, Lasaridis AN, Nilsson PM, Mouslech TF, Hitoglou-Makedou AD,
Stafylas PC, et al. The effect of rosiglitazone on novel atherosclerotic risk factors in patients with type 2 diabetes mellitus and hypertension. An open-label observational study. Metabolism 2005;54:1236-1242.
87. Holmberg A, Johnell O, Nilsson PM, Nilsson J-Å, Berglund G, Åkesson K. Risk factors for hip fractures in a middle-aged population - a study of 33 000 men and women. Ostoporosis Int 2005; 16:2185-94.
88. Ridderstråle M, Eliasson B, Cederholm J, Nilsson PM, Gudbjörnsdottir S. Obesity and cardiovascular risk factors in type 2 diabetes: Results from the Swedish national diabetes register. J Internal Med 2005 259:314-22.
89. Borgquist R, Gudmundsson P, Winter R, Nilsson P, Willenheimer R. Erectile dysfunction in healthy subjects predicts reduced coronary flow velocity reserve. Int J
Cardiol 2006;112:166-70.
90. Tell D, Nilsson PM. Early ageing in middle-aged men is associated with adverse social factors and increased mortality risk - The Malmö Preventive Project. Scand J
Public Health 2006; 34:346-52.
91. Ekberg-Aronsson M, Pehrsson K, Nilsson PM, and Löfdahl CG. Socio-economic status and lung cancer risk including histologic subtyping –a longitudinal study. Lung
Cancer 2006;51:21-9.
22

92. Nilsson PM, Hofvendahl S, Hofvendahl E, Brandt L, Ekbom A. Smoking in pregnancy in relation to gender differences in offspring adult mortality risk. Scand J Public
Health 2006;34:660-4.
93. Holmberg AH, Johnell O, Nilsson PM, Nilsson JÅ, Berglund G, Åkesson K. Risk factors for fragility fractures in middle age. A prospective population-based study of
33 000 men and women. Osteoporos Int 2006;17:1065-77.
94. * Nilsson PM, Nilsson J-Å, Berglund G. Population attributable risk (PAR) of coronary heart disease risk factors during long-term follow-up: the Malmö Preventive Project. J
Internal Med 2006;260:134-141.
95. Holmkvist J, Lyssenko V, Almgren P, Nilsson PM, Groop L. Common variants in the
HNF-1alpha and risk of type 2 diabetes. Diabetologia 2006;49:2882-2891.
96. Bertz L, Barani J, Gottsäter A, Nilsson PM, Mattiasson I, Lindblad B. Are there differences of inflammatory bio-markers between diabetic and non-diabetic patients with critical limb ischaemia? Int J Angiology 2006;25:370-7.
97. * Nilsson PM, Engström G, Hedblad B, Frystyk J, Persson M, Berglund G, Flyvbjerg A.
Plasma adiponectin levels are inversely associated with carotid intima media thickness and markers of insulin resistance in middle-aged men. ATVB
2006;26:2758-62.
98. Grelz M, Grelz H, Nilsson PM. Early menopause, smoking habits, and the risk of premature mortality and cardiovascular events in the Malmö Preventive Project.
Seminars in Cardiology 2006;12:1-7.
99 Nilsson PM, Bergkvist G, Peters A, Köpp W. Ärztef ű hrerschule Alt-Rehse--the main educational centre for promotion of Nazi medicine ideology in Germany during 1935 -
1943. Sven Med Tidskr 2006;10:199-211.
100. Sarafidis P, Lasaridis A, Nilsson PM, Pikilidou M, Stafilas P, Kanaki A, et al. Validity and reproducibility of HOMA-IR, I/HOMA-IR, QUICKI and McAuley´s indices in patients with hypertension and type 2 diabetes. J Hum Hypertension 2007;21:709-
16.
101. Borgkvist R, Nilsson PM, Gudmunsson P, Winter R, Leosdottir M, Willenheimer R.
Coronary flow velocity reserve reduction is comparable in patients with erectile dysfunction and in patients with impaired fasting glucose or well-regulated diabetes mellitus . Eur J Cardiovasc Prev Rehab 2007;14:258-64.
102. Nilsson PM, Engström G, Hedblad B. The metabolic syndrome and incidence of cardiovascular disease in non-diabetic subjects. Diabetic Medicine 2007;24:464-72.
103. Öhlin B, Rosvall M. Berglund G, Nilsson PM. Job strain in men, but not in women, predicts a significant rise in blood pressure after 6.5 years follow-up. J Hypertens
2007;25:525-31.
23

104. Eeg-Olofsson K, Cederholm J, Nilsson PM, Gudbjörnsdottir S, Eliasson B. Glycemic and risk factor control in type 1 diabetes: Results from 13,612 patients in a national diabetes register. Diabetes Care 2007;30:496-502.
105. Hedblad B, Nilsson PM, Zambanini A, Berglund G. Rosiglitazone reduces carotid intima-media thickness progression over 1 year in patients with type 2 diabetes but not in non-diabetic people who have insulin resistance alone. J Internal Med
2007;261:293-305.
106. Eliasson B, Eeg-Olofsson K, Cederholm J, Nilsson PM, Gudbjörnsdottir S, for the national Diabetes Register of Sweden. Antihyperglycaemic treatment of type 2 diabetes: Results from a national diabetes register. Diabet Metabol 2007;33:269-
276.
107. Kozakova M, Palombo C, Mhamdi L, Konrad T, Nilsson P, Staehr PB, Paterni M,
Balkau B; on behalf of the RISC Investigators. Habitual physical activity and vascular ageing in a healthy youn-to-middle-aged population. Stroke 2007;38:2549-55.
108. Ekberg-Aronsson M, Persson K, Nilsson PM, Löfdahl C-G. Mortality risks among heavy-smokers with special reference to women - A long-term follow-up of an urban population. Eur J Epidemiol 2007;22:301-9.
109. Öhlin B, Berglund G, Nilsson PM, Melander O. Job strain, decision latitude and alpha-
2B-adrenergic receptor polymorphism significantly interact, and associate with higher blood pressures in men. J Hypertens 2007; 25:1613-9.
110. Nilsson PM, Hedblad B, Donaldson J, Berglund G. Rosiglitazone reduces office and diastolic ambulatory blood pressure following one-year treatment in non-diabetic subjects with insulin resistance. Blood Pressure 2007; 16:95-100.
111.
Nordfjäll K, Österman P, Melander O, Nilsson PM, Roos G. hTERT -1327T/C polymorphism is not associated with age-related telomere attrition in peripheral blood.
Biochem Biophys Research Commun 2007;358;215-218.
112. * Genome-wide association analysis identifies three novel loci for type-2 diabetes and one for triglyceride levels. Diabetes Genetics Initiative of Broad Institute of Harvard and IMT, Lund University and NOVARTIS Institutes for Biomedical Research.
(Nilsson PM is listed as a co-author, with Leif Groop as the main representative from
Lund University). Science 2007; 316:1331-6.
113. Lyssenko V, Lupi R, Marchetti P, Del Guerra S, Orju-Melander M, Almgren P,
Sjögren M, Ling C, Eriksson KF, Lethagen ÄL, Mancarella R, Berglund G, Yumoi T,
Nilsson PM, del Prato S, Groop L. Mechanisms by which common variants in the
TCF7L2 gene increase risk of type 2 diabetes. J Clin Invest 2007;117:2155-2163.
114. Nilsson PM, Journath G, Palm K, Viigimaa M. Risk factor control in treated hypertensives from Estonia and Sweden. Blood Pressure 2007;16:301-4.
115. Leosdottir M, Nilsson PM, Nilsson JÅ, Berglund G. Cardiovascular event risk in relation to dietary fat intake in middle-aged individuals - data from The Malmö Diet and Cancer Study. Eur J Cardiovasc Prev Rehab 2007;14:701-6.
24

116. Ling C, Poulsen P, Simonsson S, Rönn T, Holmkvist J, Almgren P, Hagert P, Nilsson
E, Mabey AG, Nilsson PM, Vaag A, Groop L. Genetic and epigenetic factors are associated with expression of NDUFB6 from the respiratory chain in human muscle. J
Clin Invest 2007;117:3427-3435.
117. Journath G, Hellenius ML, Petersson U, Theobald H, Nilsson PM, for the Hyper-Q
Study Group. Gender and risk factor control in treated hypertensives – a national study in the primary health care in Sweden. Eur J Cardiovasc Prev Rehab
2008;15:258-262.
118. Petersson U, Östgren CJ, Brudin L, Ovhed I, Nilsson PM. Predictors for successful self-reported lifestyle changes in a defined middle aged population. The Söderåkra
Cardiovascular Study.
Scand J Public Health 2008;36:389-96.
119. Holmberg A, Nilsson PM, Nilsson J-A, Åkesson K. The Association Between
Hyperglycaemia and Fracture Risk in Middle-Age. A prospective, population-based study of 22 444 men and 10 902 women. J Clin Endocrin Metabol 2008; 93:815-22.
120. Borgquist R, Leósdóttir M, Nilsson P, Willenheimer R. Self-rated health and classical risk factors for coronary heart disease predict development of erectile dysfunction 25 years later. Int J Clin Pract 2008;62:206-13.
121. Ekberg-Aronsson M, Persson K, Nilsson PM, Löfdahl C-G. Hospital admission rates among men and women with symptoms of chronic bronchitis and signs of airflow limitation corresponding to the GOLD stages of chronic obstructive pulmonary disease - A population-based study. Respiratory Medicine 2008;102:109-20.
122. Mari A, Scherbaum WA, Nilsson PM, Lalanne G, Schweizer A, Dunning BE, et al.
Characterization of the Influence of Vildagliptin on Model-Assessed {beta}-Cell
Function in Patients with Type 2 Diabetes and Mild Hyperglycemia. J Clin
Endocrinol Metab 2008;93:103-9.
123. Zeggini E, Scott LJ, Saxena R, Voight BF, for the Diabetes Genetics Replication and
Meta-analysis (DIAGRAM) Consortion (Nilsson PM is listed as contributing coauthor). Meta-analysis of genome-wide association data and large-scale replication identifies several additional susceptibility loci for type 2 diabetes. Nature Genetics
2008;40:638-45.
124. Canivet C, Östergren P-O, BongKyoo C, Nilsson PM, af Sillén U, Moghadaai M,
Karasek R, Isacsson S-O. Self-reported sleeping problems as a risk factor for subsequent musculo-sceletal pain and the role of job strain; Results from a one-year follow-up study of the Malmö Shoulder Neck Study cohort. Int J Behav Med
2008;15:254-62.
125. Nordfjäll K, Eliasson M, Stegmayr B, Lundin S, Roos G, Nilsson PM . Increased abdominal obesity, adverse psychosocial factors and shorter telomere length in persons reporting subjective early ageing; the MONICA Northern Sweden Study.
Scand J Publ Health 2008; 36:744-52.
25

126. Cervin C, Lyssenko V, Lindholm E, Bakhtadze E, Nilsson P, Tuomi T, Cilio CM,
Groop L. Genetic similarities between LADA, type 1 and type 2 diabetes. Studies with the three candidate genesPAX4, PAX6 and TCF7L2. Diabetes 2008;57:1433-1437.
127. Ekesbo R, Nilsson PM, Sjölund K. Effects of Anti-secretory Factor (ASF) on the
Irritable Bowel Syndrome (IBS) - A double-blind, randomised study. Scand J Prim
Health Care 2008; 26:106-110.
128. Holmkvist J, Almgren P, Lyssenko V, Lindgren C M,
T, Nilsson P, and Groop L.
.
Eriksson K-F, Isomaa B, Tuomi
Common variants in the three MODY genes HNF-4alpha ,
GCK and HNF-1beta and future risk of type 2 diabetes. Diabetes 2008; 57:1738-44.
129. Scherbaum WA, Schweizer A, Mari A, Nilsson PM, Lalanne G, Jauffret S, Foley JE.
Efficacy and tolerability of vildagliptin in drug-naïve patients with type 2 diabetes and mild hyperglycaemia. Diabetes Obes Metab 2008;10:675-82.
130. Scherbaum WA, Schweizer A, Mari A, Nilsson PM, Lalanne G, Wang Y, Dunning BE,
Foley JE. Evidence that vildagliptin attenuates deterioration of glycaemic control during 2-year treatment of patients with type 2 diabetes and mild hyperglycaemia.
Diabetes Obes Metab 2008;10:1114-24.
131. Öhlin B, Berglund G, Nilsson PM, Melander O. Job strain, job demands and adrenergic β 1-receptor polymorphism – a possible interaction affecting blood pressures in men. J Hypertens 2008;26:1583-9.
132. Gast GC, Grobbee DE, Pop VJM, Keyzer JJ, Wijnands-van Gent CJM, Samsioe GN,
Nilsson PM, van der Schouw YT. Menopausal complaints are associated with cardiovascular risk factors. Hypertension 2008; 51:1492-8.
133. Svensson U, Nordfjäll K, Stegmayr B, Manjer J, Nilsson P, Tavelin B, Henriksson B,
Lenner P, Roos G. Breast cancer survival is associated with telomere length in peripheral blood cells Cancer Res 2008; 68:3618-23.
134. Montagnana M, Fava C, Nilsson PM, Engström G, Hedblad G, Lippi G, Minuz P,
Berglund G, Melander. The Pro12Ala polymorphism of the
PPARG gene is not associated with the metabolic syndrome in an urban based sample of middle aged
Swedes. Diabetic Medicine 2008; 25:902-8.
135. Lohmander LS, Gerhardsson M, Rollof J, Nilsson PM, Engström G. Incidence of severe knee and hip osteoarthritis in relation to different measures of body mass. A population-based prospective cohort study. Ann Rheum Dis 2009;68:490-6.
136. Rönn T, Poulsen P, Hansson O, Holmkvist J, Almgren P, Nilsson P, Tuomi T, Isomaa
B, Groop L, Vaag A, Ling C. Age influences DNA methylation and gene expression of
COX7A1 in human skeletal muscle. Diabetologia 2008;51:1159-68
137. Nordfjäll K, Eliasson M, Stegmayr B, Melander O, Nilsson P, Roos G. Telomere length is associated to obesity parameters but with a gender difference. Obesity
2008;16:2682-9.
138. Cederholm J, Eliasson B, Eeg-Olofsson K, Zethelius B, Nilsson PM, Gudbjörnsdottir
S. on behalf of the National Diabetes Register. Risk prediction of cardiovascular disease in type 2 diabetes: A risk equation from the Swedish National Diabetes
Register (NDR). Diabetes Care 2008; 31:2038-43.
26

139. Tanash H, Nilsson PM, Nilsson J-Å, Piitulainen E. Clinical course and prognosis of never-smokers with severe alpha-1-antitrypsin deficiency (PiZZ). Thorax 2008;
63:1091-5.
140. Orho-Melander M, Melander O, Guiducci C,….Nilsson PM, …Kathiresan S, et al A
Common Missense Variant in the Glucokinase Regulatory Protein Gene (GCKR) Is
Associated with Increased Plasma Triglyceride but Lower Fasting Glucose
Concentrations. Diabetes 2008;57:3112-21.
141. Nilsson PM, Engström G, Hedblad B. Long-term predictors of increased mortality risk in screening-detected patients with hypertension; the Malmö Preventive Project. J
Hypertens 2008; 26:2288-94.
142.
Lyssenko V, Jonsson A, Pulizzi N, Isomaa B, Tuomi T, Berglund G, Altshuler D,
Nilsson P, Groop L. Clinical risk factors, DNA variants, and the development of type 2 diabetes. N Engl J Med 2008; 359:2220-32.
143. Sjögren M, Lyssenko V, Jonsson A, Berglund G, Nilsson P, Groop L, Orho-Melander
M. The search for putative unifying genetic factors for components of the metabolic syndrome. Diabetologia 2008; 51:2242-51.
144. Yasuda K, Miyake K, Horikawa Y, Hara K, Osawa H, Furuta H, Hirota Y, Mori H,
Jonsson A, Sato Y, Yamagata K, Hinokio Y, Wang HY, Tanahashi T, Nakamura N,
Oka Y, Iwasaki N, Iwamoto Y, Yamada Y, Seino Y, Maegawa H, Kashiwagi A,
Takeda J, Maeda E, Shin HD, Cho YM, Park KS, Lee HK, Ng MC, Ma RC, So WY,
Chan JC, Lyssenko V, Tuomi T, Nilsson P, Groop L, Kamatani N, Sekine A,
Nakamura Y, Yamamoto K, Yoshida T, Tokunaga K, Itakura M, Makino H, Nanjo K,
Kadowaki T, Kasuga M. Variants in KCNQ1 are associated with susceptibility to type
2 diabetes mellitus. Nat Genet. 2008; 40:1092-7.
145. Journath G, Hellénius ML, Manhem K, Kjellgren KI, Nilsson PM; for the Hyper-Q
Study Group, Sweden. Association of physician's sex with risk factor control in treated hypertensive patients from Swedish primary healthcare. J Hypertens
2008;26:2050-2056.
146. Bakhtadze E, Cervin C, Lindholm E, Borg H, Nilsson P, Arnqvist HJ, et al.
Common variants in the TCF7L2 gene discriminate between autoimmune and non-autoimmune diabetes in young (15-34 years) but not in middle-aged (40-59 years) diabetic patients. Diabetologia 2008; 51:2224-32.
147. Engström G, Segelström N, Ekberg-Aronsson M, Nilsson PM, Lindgärde F, Löfdahl
CG. Plasma markers of inflammation and incidence of hospitalizations due to chronic obstructive pulmonary disease. Results from a population-based cohort study.
Thorax 2008 Nov 6. [Epub ahead of print]
148. Mokhtari A, Bellinetto-Ford L, Melander O, Nilsson PM. Determinants of increasing pulse pressure during 23 years´ follow-up as a marker of arterial stiffness and vascular ageing. Blood Pressure 2008;17:291-7.
149. Tasevska-Dinevska G, Kennedy LM, Anevski D, Nilsson P, Christensson A,
Willenheimer R. Gender differences in predictors of heart failure morbidity and mortality in an urban Swedish population: the Malmö Preventive Project. Open Heart
Failure J 2008;1:1-8.
27

150. Gast GC, Grobbee DE, Pop V, Keyzer JJ, Winands-van Gent CJ, Samsioe G,
Nilsson PM, van der Schouw YT. Vasomotor symptoms are associated with a lower bone mineral density. Menopaus 2008;16:231-8.
151. Petersson U, Östgren CJ, Brudin L, Brismar K, Nilsson PM. Low Levels of Insulin-like
Growth Factor Binding Protein-1 (IGFBP-1) is prospectively associated with Incidence of Type 2 Diabetes and impaired glucose tolerance (IGT). The Söderåkra
Cardiovascular Risk Factor Study. Diabetes Metab 2009; 35:198-205.
152. Engström G, Gerhardsson de Verdier M, Rollof J, Nilsson PM, Lohmander S. Creactive protein, metabolic syndrome and incidence of severe hip and knee osteoarthritis. A population-based cohort study. Osteoarthritis Cartilage 2009;
17:168-173.
153. Lyssenko V, Nagorny CL, Erdos MR, Wierup N, Jonsson A, Spégel P, Bugliani M,
Saxena R, Fex M, Pulizzi N, Isomaa B, Tuomi T, Nilsson P, Kuusisto J, Tuomilehto
J, Boehnke M, Altshuler D, Sundler F, Eriksson JG, Jackson AU, Laakso M, Marchetti
P, Watanabe RM, Mulder H, Groop L. Common variant in MTNR1B associated with increased risk of type 2 diabetes and impaired early insulin secretion. Nat Genet
2009;41:82-8.
154. Gudbjörnsdottir S, Cederholm J, Eeg-Olofsson K, Eliasson B, Zethelius B, Nilsson
PM; on behalf of the Swedish National Diabetes Register. Risk factor control in patients with type 2 diabetes and coronary heart disease: Findings from the Swedish
National Diabetes Register (NDR). Diabetic Medicine 2009; 26:53-60.
155. Eeg-Olofsson K, Cederholm J, Nilsson PM, Zethelius B, Nunez L, Gudbjörnsdóttir S,
Eliasson B. Overweight, obesity and cardiovascular diseases and mortality in type 2 diabetes: An observational study in 13 087 patients. Diabetologia 2009;52:65-73.
156. Pikilidou MI, Lasaridis AN, Sarafidis PA, Befani CD, Koliakos GG, Tziolas IM,
Kazakos KA, Yovos JG, Nilsson PM .
Insulin sensitivity increase after calcium supplementation and change in intraplatelet calcium and sodium-hydrogen exchange in hypertensive patients with type 2 diabetes. Diabetic Medicine 2009; 26:211-9.
157. Tarugi P, Gomaraschi M, Nilsson P, Favari E, Adorni MP, Bernini F, Sirtori CR,
Franceschini G, Calabresi L.A novel mutation in CETP gene as a cause of CETP deficiency in a Caucasian kindred. Atherosclerosis 2009;205:506-11.
158. Ahrén B, Schweizer A, Dejager S, Dunning BE, Nilsson PM, Persson M, Foley JE.
Vildagliptin Enhances Islet Responsiveness to Both Hyper- and Hypoglycemia in
Patients with Type 2 Diabetes. J Clin Endocrin Metab 2009;94:1236-43.
159. Newton-Cheh C, Larson MG, Vasan RS, Levy D, Bloch KD, Surti A, Guiducci C,
Kathiresan S, Benjamin EJ, Struck J, Morgenthaler NG, Bergmann A, Blankenberg S,
Kee F, Nilsson P, Yin X, Peltonen L, Vartiainen E, Salomaa V, Hirschhorn JN,
Melander O, Wang TJ. Association of common variants in NPPA and NPPB with circulating natriuretic peptides and blood pressure. Nat Genet 2009;41:348-53.
160. Newton-Cheh C, Johnson T, Gateva V, Tobin MD, Bochud M, Coin L, Najjar SS,
Zhao JH, Heath SC, Eyheramendy S, Papadakis K, Voight BF, Scott LJ, Zhang F,
28

Farrall ... Nilsson P, … Melander O, Loos RJ, Elliott P, Abecasis GR, Caulfield M,
Munroe PB. Genome-wide association study identifies eight loci associated with blood pressure. Nat Genet. 2009;41:666-76.
161. Nilsson PM, Xinjun Li, Sundquist J, Sundquist K Cardiovascular Disease Risk in
Mothers from two Generations in relation to number of offspring born Small for
Gestational Age – a Follow-up national Study of 3.3 million Births. Acta Paediatrica
2009; 98:985-9.
162. Smith JG, Melander O, Lövkvist H, Hedblad B, Engström G, Nilsson P, Carlson J,
Berglund G, Norrving B, Lindgren A. Common genetic variants on chromosome 9p21 confers risk of ischemic stroke: a large-scale genetic association study. Circ
Cardiovasc Genet 2009;2:159-64.
163. Tasevska-Dinevska G, Kennedy L, Nilsson PM, Willenheimer R. Gender aspects on heart failure incidence and mortality in a middle-aged, urban, community-basedpopulation sample: the Malmö Preventive Project. Eur J Epidemiol 2009;24:249-57.
164. Narayan KM, Weber MB; Gulcher J, Stefansson K; and Lyssenko V, Nilsson P,
Groop L. Clinical risk factors, DNA variants, and the development of type 2 diabetes.
(Letters to the Editor and authors´ reply). N Engl J Med 2009;360:1360-1.
165. Muscelli E, Kozàkovà M, Flyvbjerg A, Kyriakopoulou K, Astiarraga BD, Glintborg D,
Konrad T, Favuzzi A, Petrie J; RISC investigators (inlcluding Nilsson PM). The effect of menopause on carotid artery remodeling, insulin sensitivity, and plasma adiponectin in healthy women. Am J Hypertens 2009;22:364-70.
166. Hyvarinen M, Tuomilehto J, Laatikainen T, Soderberg S, Eliasson M, Nilsson P, Qiao
Q. The impact of diabetes on coronary heart disease differs from that on ischaemic stroke with regard to the gender. Cardiovasc Diabetol 2009;8:17 .
167. Martin M, Gottsäter A, Nilsson PM, Mollnes TE, Lindblad B. Complement activation and plasma levels of C4-binding protein in critical limb ischaemia. J Vasc Surg 2009;
50:100-6.
168. Brito EC, Lyssenko V, Renström F, Berglund G, Nilsson PM, Groop L, Franks PW.
Previously associated type 2 diabetes variants may interact with physical activity to modify the risk of impaired glucose regulation and type 2 diabetes: a study of 16,003
Swedish adults. Diabetes 2009;58:1411-8.
169.
Petersson U, Östgren CJ, Brudin L, Nilsson PM. A consultation-based method is equal to SCORE and an extensive laboratory-based method in predicting risk of future cardiovascular disease. Eur J Cardiovasc Prev Rehab 2009;16:536-40.
170. Nilsson PM, Cederholm J, Eeg-Olofsson K, Eliasson B, Zethelius B, Fagard R,
Gudbjörnsdottir S. Smoking as an independent risk factor for myocardial infarction or stroke in type 2 diabetes: A report from the Swedish National Diabetes Register
(NDR). Eur J Cardiovasc Prev Rehab 2009;16:506-12.
171. de Rooij SR, Nijpels G, Nilsson PM, Nolan JJ, Gabriel R, Bobbioni-Harsch E,
Mingrone G, Dekker JM; the RISC Investigators. Low grade chronic inflammation in the RISC population: associations with insulin resistance and cardiometabolic risk profile. Diabetes Care. 2009;32:1295-301.
29

172. Muscelli E, Kozàkovà M, Flyvbjerg A, Kyriakopoulou K, Astiarraga BD, Glintborg D,
Konrad T, Favuzzi A, Petrie J; RISC investigators (Nilsson PM is listed as collaborator). The effect of menopause on carotid artery remodeling, insulin sensitivity, and plasma adiponectin in healthy women. Am J Hypertens 2009;22:364-
70.
173. Jonsson A, Renström F, Lyssenko V, Brito EC, Isomaa B, Berglund G, Nilsson PM,
Groop L, Franks PW. Assessing the effect of interaction between an FTO variant
(rs9939609) and physical activity on obesity in 15,925 Swedish and 2,511 Finnish adults. Diabetologia. 2009;52:1334-8.
174. Nilsson PM, Cederholm J, Eeg-Olofsson K, Eliasson B, Zethelius B, and
Gudbjörnsdóttir S, for the Swedish National Diabetes Register (NDR)
Pulse pressure strongly predicts risk of cardiovascular disease in patients with type 2 diabetes from the Swedish National Diabetes Register (NDR). Diabetes and
Metabolism 2009;35:439-46.
175. Gastaldelli A, Kozakova M, Højlund K, Flyvbjerg A, Favuzzi A, Mitrakou A, Balkau B;
RISC Investigators (Nilsson PM is listed). Fatty liver is associated with insulin resistance, risk of coronary heart disease, and early atherosclerosis in a large
European population. Hepatology 2009;49:1537-44.
176. Jonsson A, Isomaa B, Tuomi T, Taneera J, Salehi A, Nilsson P, Groop L, Lyssenko
V. A variant in the KCNQ1 gene predicts future type 2 diabetes and mediates impaired insulin secretion. Diabetes 2009;58:2409-13.
177. Cederholm J, Zethelius B, Nilsson PM, Eeg-Olofsson K, Eliasson B, Gudbjörnsdottir
S; on behalf of the Swedish National Diabetes Register. Effect of tight control of
HbA
1c
and blood pressure on cardiovascular diseases in type 2 diabetes: An observational study from the Swedish National Diabetes Register (NDR). Diabetes
Res Clin Pract;86:74-81.
178. Pikilidou MI, Befani CD, Sarafidis PA, Nilsson PM, Koliakos GG, Tziolas IM, Kazakos
KA, Yovos JG, Lasaridis AN. Oral calcium supplementation ambulatory blood pressure and relation to changes in intracellular ions and sodium-hydrogen exchange. Am J Hypertens 2009;22:1263-9.
179. Natali A, Muscelli E, Casolaro A, Nilsson P, Melander O, Lalic N, Ferrannini E, Petrie
JR. Metabolic characteristics of prehypertension: role of classification criteria and gender. J Hypertens 2009;27:2394-402.
180. Kong A, Steinthorsdottir V, Masson G, Thorleifsson G, Sulem P, Besenbacher S,
Jonasdottir A, Sigurdsson A, Kristinsson KT, Jonasdottir A, Frigge ML, Gylfason A,
Olason PI, Gudjonsson SA, Sverrisson S, Stacey SN, Sigurgeirsson B,
Benediktsdottir KR, Sigurdsson H, Jonsson T, Benediktsson R, Olafsson JH,
Johannsson OT, Hreidarsson AB, Sigurdsson G; DIAGRAM Consortium (including
Nilsson P), Ferguson-Smith AC, Gudbjartsson DF, Thorsteinsdottir U, Stefansson K.
Parental origin of sequence variants associated with complex diseases. Nature
2009;462:868-74.
30

181. Perry JR, Weedon MN, Langenberg C, Jackson AU, Lyssenko V, Sparsø T,
Thorleifsson G, Grallert H, Ferrucci L, Maggio M, Paolisso G, Walker M, Palmer CN,
Payne F, Young E, Herder C, Narisu N, Morken MA, Bonnycastle LL, Owen KR,
Shields B, Knight B, Bennett A, Groves CJ, Ruokonen A, Jarvelin MR, Pearson E,
Pascoe L, Ferrannini E, Bornstein SR, Stringham HM, Scott LJ, Kuusisto J, Nilsson
P, Neptin M, Gjesing AP, Pisinger C, Lauritzen T, Sandbaek A, Sampson M; MAGIC,
Zeggini E, Lindgren CM, Steinthorsdottir V, Thorsteinsdottir U, Hansen T, Schwarz P,
Illig T, Laakso M, Stefansson K, Morris AD, Groop L, Pedersen O, Boehnke M,
Barroso I, Wareham NJ, Hattersley AT, McCarthy MI, Frayling TM. Genetic evidence that raised sex hormone binding globulin (SHBG) levels reduce the risk of type 2 diabetes. Hum Mol Genet. 2010;19:535-44.
182. Fedorowski A, Stavenow L, Hedblad B, Berglund G, Nilsson PM, Melander O.
Consequences of orthostatic blood pressure variability in middle-aged men (The
Malmö Preventive Project). J Hypertens. 2010;28:551-9.
183. Khalili P, Flyvbjerg A, Frystyk J, Lundin F, Jendle J, Engström G, Nilsson PM. Total adiponectin does not predict cardiovascular events in middle-aged men in a prospective, long-term follow-up study. Diabetes Metab 2010;36:137-43.
184. Fedorowski A, Stavenow L, Hedblad B, Berglund G, Nilsson PM, Melander O.
Orthostatic hypotension predicts all-cause mortality and coronary events in middleaged individuals (The Malmo Preventive Project). Eur Heart J 2010;31:85-91.
185. Leosdottir M, Willenheimer R, Plehn J, Borgquist R, Gudmundsson P, Nilsson PM,
Gudnasson V. Myocardial structure and function by echocardiography in relation to glucometabolic status in elderly subjects from two population-based cohorts: a crosssectional study. Am Heart J 2010;159:414-420.e4
186. Saxena R, Hivert MF, Langenberg C, Tanaka T, Pankow JS, Vollenweider P,
Lyssenko V, …..Nilsson P, ….Groop L, Wareham NJ, Watanabe RM. Genetic variation in GIPR influences the glucose and insulin responses to an oral glucose challenge.
Nat Genet. 2010;42:142-8.
187. Journath G, Hellénius ML, Carlsson AC, Wändell PE, Nilsson PM. Physicians' gender is associated with risk factor control in patients on antihypertensive and lipid lowering treatment. Blood Press. 2010 May 7.
[Epub ahead of print]
188. Enhörning S, Wang TJ, Nilsson PM, Almgren P, Hedblad B, Berglund G, et al.
Plasma Copeptin and the Risk of Diabetes Mellitus. Circulation. 2010; 121:2102-8.
189. Eeg-Olofsson K, Cederholm J, Nilsson PM, Zethelius B, Svensson AM,
Gudbjörnsdóttir S, Eliasson B. Glycemic control and cardiovascular disease in 7454 patients with type 1 diabetes: an observational study from the Swedish National
Diabetes Register (NDR). Diabetes Care. 2010;33:1640-6.
190. Tanash HA, Nilsson PM, Nilsson JA, Piitulainen E. Survival in severe alpha-1-antitrypsin deficiency (PiZZ). Respir Res. 2010;11:44.
191. Gast GC, Samsioe GN, Grobbee DE, Nilsson PM, van der Schouw YT. Vasomotor
31

symptoms, estradiol levels and cardiovascular risk profile in women . Maturitas.
2010;66:285-90.
192. Larsen JT, Fagerquist M, Holdrup M, Christensen B, Sigalin C, Nilsson PM. High prevalence of metabolic risk factors associated with cardiovascular disease in 687 schizophrenic patients treated with atypical antipsychotic drugs – Results from a joint
Danish-Swedish cross-sectional study. Nord J Psychiatry. 2010 May 20. [Epub ahead of print]
193. Zhou XH, Qiao Q, Zethelius B, Pyörälä K, Söderberg S, Pajak A, Stehouwer CD,
Heine RJ, Jousilahti P, Ruotolo G, Nilsson PM, Calori G, Tuomilehto J; for the
DECODE Study Group. Diabetes, prediabetes and cancer mortality. Diabetologia.
2010; 53:1867-76.
194. Eliasson B, Eriksson M, Eeg-Olofsson K, Zethelius B, Nilsson P, Gudbjörnsdottir D, for the NDR. Blood lipids in 75048 type 2 diabetic patients. A population-based survey from the Swedish National Diabetes Register. Eur J Cardiovas Prev Rehab
2010 (In press).
195. Voight BF, … Nilsson P,...Altshuler D, Boehnke M, McCarthy MI; MAGIC investigators; GIANT Consortium. Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis. Nat Genet 2010;42:579-89.
196. Vickers AJ, Cronin AM, Björk T, Manjer J, Nilsson PM, Dahlin A, Bjartell A, Scardino
PT, Ulmert D, Lilja H. Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study. BMJ. 2010 Sep 14;341:c4521. doi: 10.1136/bmj.c4521
.
197. Eeg-Olofsson K, Cederholm J, Nilsson PM, Zethelius B, Svensson AM,
Gudbjörnsdóttir S, Eliasson B. New aspects of HbA1c as a risk factor for cardiovascular diseases in type 2 diabetes: an observational study from the Swedish
National Diabetes Register (NDR). J Intern Med. 2010 Jul 21. [Epub ahead of print].
198. Cederholm J, Gudbjörnsdottir S, Eliasson B, Zethelius B, Eeg-Olofsson K, Nilsson
PM; on behalf of the NDR. Systolic blood pressure and risk of cardiovascular diseases in type 2 diabetes: an observational study from the Swedish national diabetes register. J Hypertens 2010;28:2026-2035.
199. Anderwald C, Stadler M, Golay A, Krebs M, Petrie J, Luger A; RISC
Investigators (including Nilsson PM). Impact of family history on relations between insulin resistance, LDL cholesterol and carotid IMT in healthy adults. Heart.
2010;96:1191-200.
32

1.
2.
3.
4.
5.
Möller L, Nilsson PM, Solstad K, Jörgensen T. Risk of psychosocial stress combined with hypogonadal function in middle-aged men – a prospective study of ischaemic heart disease manifestations. (Manuscript).
Leosdottir M Nilsson PM, Willenheimer R, Nilsson J-Å, Berglund G. Fasting plasma glucose predicts traditional cardiovascular risk factors among non-diabetic subjects.
Scand Cardiovasc J 2005;39 (suppl. 53): 38 (A128).
(+ Manuscript).
Mogilnaya I, Leosdottir M, Nilsson J-Å, Nilsson PM. Gender differences in the prediction of acute coronary events and stroke by fasting and 2-h plasma glucose:
The Malmö Preventive Project. (Manuscript).
Nilsson PM, Xinjun Li, Sundquist J, Sundquist K. Maternal reproductive history and sibling rank predict cardiovascular disease and total mortality based on national multigeneration register data for 2.2 million Swedish women and men. (Manuscript).
Kadam U, Holmberg A, Blagojevic M, Nilsson PM, Åkesson K. Cardiovascular disease risk factors and future osteoarthritis: a population-based cohort study in men and women from Malmö, Sweden. Ann Rheum Dis 2009 (revised manuscript).
33

1. Nilsson P. Lindholm L, Melander A, Scherstén B, Hesch RD.
U-cAMP - A marker for hypertension? Ann Clin Res 1988;20 (suppl 48):40.
2.
3.
Nilsson P. Non-pharmacological treatment of hypofibrinolysis. In: Clinical aspects of fibrinolysis.
(Ed.) TK Nilsson, K Boman, JH Jansson. Almqvist &
Wiksell International, Stockholm 1991:131-40.
4.
5.
Nilsson P. Hyperinsulinemia in treated hypertensives. Intervention with non-pharmacological treatment. In: Scand Symposium: Prophylaxis of coronary disease.
Are new strategies needed? UpJohn Oslo, 1991:41-50.
Nilsson P, Lindholm L, Scherstén B. High prevalence of hypertension in lower social groups is not explained by a "general susceptibility" for biological risk factors. J Hypertens 1992;10(suppl 4):s142 .
6.
7.
Nilsson P. Lipid alterations and hypertension. In: Second international symposium on hypertension.
1993; 7(suppl.7):116 - 26.
Oporto, Portugal. Arquivos de Medicina,
Nilsson P. Sodium and hypertension - the Swedish experience.
Nieren- und Hochdruckkrankheiten 1994; 23(suppl 1): S28 - S31.
Nilsson P, Möller L, Östergren P-O. Social class and cardiovascular disease - an update. Scand J Soc Med 1995; 23:3-8.
8.
9.
Nilsson P. Diabetes and Hypertension . In: Textbook of Diabetes . Chapter 56.
(Eds.) Pickup JC, Williams G. Blackwell Scientific Publications. London, 1997, revised 2002.
Nilsson P. Diabetes and Syndrome X in hypertension - population aspects.
J Hum Hypertension 1996; 10(suppl 1): S81-S84.
10. Nilsson P. New drugs and clinical trials in diabetes and hypertension. Exp Clin
Endocrinol Diabetes 1997; 105(suppl 2): 64-9.
11. Nilsson P, Julius S (eds.). Metabolic disturbances in arterial hypertension. Blood
Pressure 1996 (suppl.1).
12. Nilsson P. New aspects of diabetes therapy. Exp Clin Endocrinol Diabetes 1997;
105:5(A79).
13. Nilsson P. Hypertension and diabetes mellitus. In: (Ed. L. Hansson) Hypertension and concomitant disorders , pp. 1-13. Science Press.
London, 1997.
14. Nilsson P. Hypertension and hyperlipidaemia. In: (Ed. L. Hansson) Hypertension and concomitant disorders , pp. 27-33. Science Press.
London, 1997.
15. Nilsson P, Endre T. The impact of metabolic risk factors on the management of hypertension. Internat Trends in Hypertens 1998; nr. 3:5-8.
34

16. Nilsson P. Review: Hyperinsulinaemia and the risk of atherosclerotic disease.
Baltic Atherosclerosis J 1999; 1:45-48.
17. Erhardt L, Nilsson P. Quality assurance of secondary prevention - a solution to better implementation of guidelines. Scand Cardiovasc J 1999; 33:3-4.
18. Svartvik L, Nilsson P. Synpunkter på begrepper Kasam. In: Kumlien: "Röster om
Kasam" . FRN, Stockholm, 1999.
19. Nilsson P, Orth-Gomér K (Eds.). Self-rated health in an European perspective . FRN.
Stockholm, 2000.
20. Nilsson P. Hypertension and metabolic risk factors. Medical Practice (Ukraine)
1999; 4:73-76.
21. Nilsson P, Berglund G. Prevention of cardiovascular disease and diabetes - A review with ex amples from the Malmö Preventive Project. J Internal Med 2001:248:455-62.
22. Nilsson P. Research in hypertension – the Swedish experience. Arterial
Hypertension (Poland) 2000;4:167-71.
23. Nilsson P. How should hypertension be managed in diabetes? In: (Eds.) Gill G,
Pickup J, Williams G. Difficult Diabetes . pp. 278-93. Blackwell Science Ltd.
London, 2001 .
24. Nilsson P. Are we all programmed for hypertension and cardiovascular disease?
Focus on the role of foetal factors. Arterial Hypertension (Poland) 2001;5
(supplement):43-8 .
25. Nilsson P, Berglund G. Prevention of cardiovascular disease and diabetes. Lessons from the Malmö Preventive Project. J Internal Med 2001;248:455-62 .
26. Nilsson P, Båvenholm P. Stress and gonadal function in middle-aged males.
Excerpta Medica International Congress Series 2002;1229:9-16.
27. Getz L, Nilsson PM, Hetlevik I. A matter of the heart – the clinical consultation in an evidence-based world. Scand J Prim Health Care 2003;21:1-9 .
28. Åkerstedt T, Nilsson PM. Sleep as restitution: an introduction. J Internal Med
2003;254:6-12 .
29. Nilsson PM. Reducing the risk of stroke in elderly patients with hypertension: A critical review of the efficacy of antihypertensive drugs. Drugs & Aging 2005;22:517-24.
30. Nilsson PM. VALUE: new data in hypertension treatment. Hospital Pharmacy
Europe 2005; March-April (No. 19):36-37.
31. Nilsson PM. Diabetes and obesity: new data on mechanisms and intervention trials.
Expert Rew Cardiovasc Therapy 2005;3:1-5.
32. Nilsson PM. Fetal origins of hypertension and diabetes – a new perspective.
Romanian Journal of Cardiology 2005; 20:223-5.
35

33. Nilsson PM. Book review. Mulrowe CD (ed.), Evidence-based hypertension.
Evidence-based Cardiovasc Med 2005; August ( www.sciencedirect.com
)
34. Nilsson PM. Gener/environment interaction: Thrifty genotype versus thrifty phenotype. In: The Metabolic syndrome at the beginning of the XXI st
century. A genetic and molecular aspproach.
(Eds. Serrano Rios M, Caro JF, Carraro R,
Gutiérez Fuentes JA). Elsevier. Madrid, 2005. (ISBN: 84-8174-892-7).
35. Sarafidis P, Nilsson PM. The effects of thiazolidinedione compounds on blood pressure levels – a systematic review. Blood Pressure 2006; 15:135-150.
36. Sarafidis P, Nilsson PM. The Metabolic Syndrome: a glance in its history. J
Hypertens 2006; 24:621-6.
37. Nilsson PM, Cifkova R, Kjeldsen SE. Update on Hypertension Management:
Treatment of hypertension in patients with type 2 diabetes mellitus. J Hypertens
2006;24:208-10.
38. Nilsson PM, Berglund G. Beta-receptor blockers in primary prevention for cardiovascular disease – forgotten benefits? J Hum Hypertens 2006; 20:719-21.
39. Nilsson PM, Cifkova R, Kjeldsen SE, Mancia G. Update on Hypertension
Management: Prevention of type 2 diabetes mellitus with antihypertensive drugs. Eur
Soc Hypertens Newsletter 2006; 7:Nr. 27. J Hypertens 2006; 24:2478-2482.
40. Nilsson PM. Optimizing the Pharmacologic Treatment of Hypertension : BP Control and Target Organ Protection. Am J Cardiovasc Drugs 2006;6:287-95.
41. Nilsson PM, Holmäng A. Introduction to Mini-symposium on developmental origins of adult disease. J Internal Med 2007;261:410-1.
42. Nilsson PM. ESH update on hypertension management (Letter). J Hypertens
2007;25:1101-2.
43. Nilsson PM. Blood pressure lowering drugs not considered as antihypertensives.
Curr Hypertens Reports 2007;9:249-50.
44. Nilsson PM. Drug-induced new onset diabetes in hypertension: does it matter?
(Editorial). J Hypertens 2007;25:1201-4.
45. Nilsson PM. Early vascular ageing and hypertension – A new model for understanding cardiovascular risk.
Curr Hypertens Rev 2007;3:133-136.
46. Nilsson PM. Is weight loss beneficial for reduction of morbidity and mortality? What is the controversy about? Diabetes Care 2008; 31 (suppl. 2):S278-S283.
47. Nilsson PM. Early vascular ageing (EVA) – consequences and prevention. Vascular
Health and risk management 2008;4:547-52.
48. Nilsson PM. Early, Optimal Blood Pressure Control for High-Risk Patients. European
Cardiovascular Disease 2006 - May 2006.
36

49. Authors/Task Force Members: Mancia G, De Backer G, Dominiczak A, Cifkova R,
Fagard R, ….Nilsson PM, ……2007 Guidelines for the Management of Arterial
Hypertension: The Task Force for the Management of Arterial Hypertension of the
European Society of Hypertension (ESH) and of the European Society of Cardiology
(ESC). Eur Heart J 2007; 28:1462-536, J Hypertens 2007;25:1105-87, G Ital
Cardiol (Rome) 2007;8:389-479
50. Nilsson PM. Why does sleep disturbances increase the risk of diabetes mellitus, and is there really a gender difference?. Sleep Medicine 2008;9:219-20.
51. Nilsson PM. The metabolic syndrome: a therapeutic challenge. (Book review). J
Hypertens 2007;25:2359-2360.
52. Nilsson PM. Cardiovascular risk in the Metabolic syndrome: Fact or fiction? Curr
Cardiol Rep 2007; 9:479-485 .
53. Nilsson PM. High-normal blood pressure and future risks – a new concern for clinicians? (Editorial). Eur Heart J 2007;28:2832-2833.
54. Nilsson PM. Hypertension in Diabetes. In: (Eds. Mancia G, Grassi G) European
Society of Hypertension. Textbook on Hypertension.
2008
55. Nilsson PM. Cardiovascular Risk in the Metabolic Syndrome: Fact or Fiction? Curr
Cardiol Rep 2007; 9:479-485.
56. Nilsson P. Antihypertensive efficacy of zofenopril compared with atenolol in patients with mild to moderate hypertension. Blood Press 2007;16 (Suppl 2):25-30.
57. Nilsson PM, Lurbe E, Laurent S. The early life origins of vascular ageing and cardiovascular risk: the EVA syndrome. (Review) . J Hypertens 2008; 26:1049-1057.
58. Nilsson PM. Are the thiazolidinediones a safe drug choice or not for elderly patients with type 2 diabetes? Ageing Health 2008;4:131-135.
59. Nilsson PM. Is screening for the metabolic syndrome useful or not? (Editorial) Eur J
Cardiovasc Nurs 2008;7:94-5.
60.
Nilsson PM. Is adiponectin and its genetic regulators useful or not for prediction of carotid intima-media thickness and coronary heart disease? (Editorial) Eur Heart J
2008;29:293-5.
61. Redon J, Cifkova R, Laurent S, Nilsson P, Narkiewicz K, Erdine S, Mancia G, on behalf of the Scientific Council of the European Society of Hypertension. The metabolic syndrome in hypertension: European society of hypertension position statement. J Hypertens 2008;26:1891-1900.
62. Cifkova R, Nilsson PM. Statins and hypertension.
J Hypertens. 2009;27:662-5.
63. Åkerstedt T, Nilsson PM. Recovery through sleep.
Chapter in Text-book 2008.
64. Nilsson PM. Elevated blood pressure predicts type 2 diabetes, but why? J Hypertens
2008;26:1740-1.
37

65. Nilsson PM, Journath G. Effective consultation for patients with hypertension: does the physician's gender matter for risk-factor control? Womens Health (Lond Engl).
2008;4:433-4.
66. Redon J, Cifkova R, Laurent S, Nilsson P, Narkiewicz K, Erdine S, Mancia G.
Mechanisms of hypertension in the cardiometabolic syndrome. J Hypertens
2009;27:441-451.
67. Nilsson PM. Adverse social factors can predict hypertension – but how? (Editorial).
Eur Heart J 2009; 30:1305-6.
68.
Nilsson PM, Boutouyrie P, Laurent S. Vascular aging: A tale of EVA and ADAM in cardiovascular risk assessment and prevention. (Brief Review) Hypertension 2009;
54:3-10.
69. Samsioe G, Lidfeldt J, Nerbrand C, Nilsson P. The Women's Health in the Lund Area
(WHILA) study-An overview. Maturitas. 2010;65:37-45.
70. Nilsson PM, Fagerström KO. Smoking cessation: it is never too late. Diabetes Care.
2009;32 Suppl 2:S423-5.
71. Nilsson PM. Hypertension and diabetes: should we treat early surrogates? What are the cons? Diabetes Care. 2009;32 Suppl
72. Fagard RH, Nilsson PM. Smoking and diabetes--the double health hazard! Prim
Care Diabetes. 2009;3:205-9.
73. Mancia G, Laurent S, Agabiti-Rosei E, Ambrosioni E, Burnier M, Caulfield MJ,
Cifkova R, Clément D, Coca A, Dominiczak A, Erdine S, Fagard R, Farsang C,
Grassi G, Haller H, Heagerty A, Kjeldsen SE, Kiowski W, Mallion JM, Manolis A,
Narkiewicz K, Nilsson P, Olsen MH, Rahn KH, Redon J, Rodicio J, Ruilope L,
Schmieder RE, Struijker-Boudier HA, van Zwieten PA, Viigimaa M, Zanchetti A.
Reappraisal of European guidelines on hypertension management: a European
Society of Hypertension Task Force document. J Hypertens. 2009 Oct 15. [Epub ahead of print]. Blood Press. 2009;18:308-47.
74. Nilsson PM. ACCORD and Risk-Factor Control in Type 2 Diabetes. N Engl J Med.
2010;362:1628-30.
75. Olsen MH, Mallion JM, Rahn KH, Erdine S, Viigimaa M, Laurent S, Agabiti-Rosei E,
Mancia G, Schmieder RE, Cifkova R, Dominiczak A, Kjeldsen SE, Redon J, Zanchetti
A, Nilsson P, Narkiewicz K; ESH Council. Agreement within Europe about antihypertensive treatment and education - results from the European Society of
Hypertension questionnaire. J Hypertens 2010;28:1593-4.
76. Carlberg B, Nilsson PM. Hypertension in the Elderly: What Is the Goal Blood
Pressure Target and How Can This Be Attained? Curr Hypertens Rep. 2010 Aug
14. [Epub ahead of print]
38

(* = referee-evaluated papers)
1*. Nilsson P. Hälsa, sjukdom och klass. Läkartidningen 1981;78:2664-5.
2*. Nilsson P. Sjukdom och klass i Sverige - nya rön. Läkartidningen
1984;81:91-4.
3. Nilsson P. Hjärt-kärlsjukdomar. I:
ABF-brevskolan, 1984.
Varför blir vi sjuka?
Stockholm:
4. Nilsson P. Klass och ohälsa i Sverige - en utmaning för vården.
SACO-SR-tidningen 1984;5:26-8.
5*. Nilsson P. Barnolycksfall i Kalmar 1985-6. Metoder för registrering.
Socialmedicinsk tidskrift 1987;64:438-41.
6.
7.
Nilsson P. Hypertoni och atheroscleros. Hässle Information 1989;2:25-32.
Pollare T, Nilsson P. Multifaktoriell riskprofil hos hypertoniker. Merck,
Sharp & Dome AB. Stockholm, 1990.
8*. Nilsson P. Kommundiagnostik i grundutbildningen av läkare. AllmänMedicin
1990;5:196.
9. Nilsson P. Hypertension - en delaspekt av det "metabola syndromet".
Hypertoninytt 3/1990.
10. Nilsson P. Nya perspektiv på hypertoni. Rapport från 13th Scientific
Meeting of the International Society of Hypertension i Montreal 24-29.6.1990.
Hässle Information 9/90.
11. Nilsson P. Arbetslöshet och ohälsa - utmaning för distriktsläkaren.
Läkartidningen (Medicinsk kommentar) 1991; 39: 3161-2.
12. Nilsson P, Hellenius ML, Johansson J, Karlberg BE, Landin-Wilhelmsen K,
Walldius G. Det metabola syndromet. Ny syn på kardiovaskulära riskfaktorer.
(Red.) P. Nilsson. ASTRA AB. Södertälje, 1991.
13. Nilsson P. Hyperinsulinemi och metabola störningar hos behandlade hypertoniker - Dalbystudien. Basel II . Sandoz AB, 1991;13-16.
14*. Nilsson P, Lindholm L, Scherstén B. Metabolt angiopatiskt syndrom - samspel mellan metabolism och kärlvägg. Läkartidningen 1992;89:2437-9.
15. Nilsson P. Essentiell hypertoni - aktuella synpunkter på epidemiologi och risk. Medicinskt Magasin 1992;3:3-6.
16. Nilsson P. Metabola syndromet - en ny syn på kardiovaskulär sjukdom.
Klinik & Terapi 1992;3:73-6.
17. Nilsson P. Metabola syndromet - en ny syn på hjärt-kärlsjukdom.
Margasinet (Margarinbolaget) 1992;3:4-6.
39

18. Nilsson P, Johansson B. Nedsatt fibrinolys. bakgrund, kardiovaskulär risk samt läkemedelsaspekter. (broschyr) Pfizer AB, 1992.
19. Nilsson P. Fibrinogen - en kardiovaskulär riskfaktor. Rapport Intern symp
Wien 1992. Hässle Information 1992;8:27-31.
20*. Nilsson P. Allmänläkaren och preventionen - ett teoretiskt, praktiskt och etiskt problem. AllmänMedicin 1993;14:22-4.
21. Nilsson P. Insulinresistens: betydelse och behandlingsmöjligheter.
HypertoniNytt 1993;9:6-7.
22. Gunnarsson C, Jansson A C, Isacsson Å, Nilsson P, Nordenskjöld C,
Rasmusson B. Tryggare kan barnen vara. Barnolycksfallsprojektet i Dalby.
Centrum för samhällsmedicin, Dalby/Lund, 1993.
23. Nilsson P. Kongressrapport från "Hypertension in the Community".
HypertoniNytt 1993;9:40-3.
24. Nilsson P. Nya behandlingsrekommendationer för hypertoni vållar debatt.
Hässle information 1993;10:11-4.
25. Nilsson P. Rapport från tredje internationella konferensen i preventiv kardiologi. Medicinskt Magasin 1993;5:9-11.
26. Nilsson P., Lundgren H. Rökningens metabola effekter - möjligt att påverka med intervention? Medicinskt Magasin 1994; 6(nr.1): 3-5.
27*. Nilsson P, Söderström M, Himmelmann A. Intrauterin tillväxthämning - en riskfaktor för typ-2 diabetes och hjärt-kärlsjukdom? Läkartidningen, 1994; 91:2403-5.
28*. Nilsson P. Insulinresistens - nya aspekter på bakgrund och behandling.
Nordisk Medicin 1994; 109: 151 - 3.
29. Nilsson P. Könsskillnader i metabolism och blodtryckskontroll - delaspekter av det
"metabola syndromets" patofysiologi. Medicinskt Magasin 1994; nr. 4: 3-7.
30. Nilsson P. Låg födelsevikt - en riskfaktor för hypertoni och typ-2 diabetes ?
KÄRiLET 1994; Nr 2: 14 - 17.
31*. Nilsson P, Persson B. Dödsorsaker bland svenska provinsialläkare 1840 - 1879.
AllmänMedicin 1995; 16:30-1.
32*. Nilsson P, Himmelman A. Svensk hypertoniforskning idag - obesvarade forskningsfrågor. AllmänMedicin 1995; 16: 95 - 7.
33. Nilsson P. Metabola biverkningar av antihypertensiv medicinering - behov av studier. Blodtrycket 1994; 10: 68 - 9.
34. Nilsson P. William Harvey - banbrytare inom cirkulationsfysiologin. Hässle
Information 1994; nr. 6: 13 - 17.
40

35. Nilsson P, Cederberg U, Holmdahl L, Söderström M. Kan intrauterin tillväxthämning utgöra en riskfaktor för typ-2 diabetes och hjärt-kärlsjukdom ?
Medicinskt Forum 1995; nr. 1: 38 - 40.
36. Hagström B, Nilsson P. Astmautveckling i vuxen ålder. Finns det samband med låg födelsevikt ? Medicinskt Forum 1995; nr. 3: 32 - 33.
37. Nilsson P. Insulinresistens och uppkomst av typ-2 diabetes. Medicinskt Magasin
1995; nr. 2: 4 - 7.
38. Nilsson P. Rökning, metabolism och hjärtkärlsjukdom. KÄRiLET 1995; 7: 10-12.
39*. Nilsson P, Landin-Olsson M, Vessby B. Riskfaktorerna hypertoni och lipidrubbning vid diabetes mellitus. State-of-the-Art. MARS-dokument på CD-rom. Socialstyrelsen.
Stockholm, 1997. (Reviderad 1999).
40. Nilsson P. Hypertoni och diabetes mellitus - praktiska riktlinjer vid behandling.
Blodtrycket 1995; 11: 81 - 85.
41. Nilsson P. Nedsatt kognitiv funktion och sänkt livskvalitet vid hypertoni. Medicinskt
Magasin 1996; nr 1: 18 - 22.
42*. Nilsson P. Sjukdomar och sjukvård på Öland från dåtid till nutid. Årsbok för
Sydsvenska medicinhistoriska sällskapets årsskrift 1995; 161 - 71.
43*. Kjellström T, Nilsson P. Blodfettrubbningar. Läkemedelsboken 1997/98; sid. 263-75.
Stockholm, 1997. (Reviderad 1999).
44. Jeppsson A, Nilsson P. Screening när resurserna är begränsade (recension).
Läkartidningen 1996; 93: 74.
45. Nilsson P, Eriksson K-F. Hellénius M-L. Motionens betydelse för metabolism och hjärtkärlsjukdom - bakgrund och rekommendationer (broschyr) MSD, 1996.
46*. Nilsson P. Stress, neuroendokrin reglering och metabol kontroll vid diabetes
Läkartidningen 1997; 94: 145-7.
47*. Nilsson P, Isacsson Å. Prevention och folkhälsoarbete i primärvård - lättare sagt än gjort. Läkartidningen 1998; 95:1810-15.
48*. Nilsson P, Hellénius M-L. Nya rön om rökavvänjning i primärvård - en litteraturgenomgång. AllmänMedicin 1997; 18:94-98.
49. Nilsson P. Kan infektion med Helicobacter pylori och Chlamydia pneumoniae ge upphov till hjärtkärlsjukdom? Svensk Cardiologi 1996; nr 4: 8-10.
50. Nilsson P. Vårdkedjan vid diabetes. DiabetologNytt 1997; nr. 1.
51. Nilsson P. Rökning, insulinresistens samt risk för diabetes. DiabetologNytt 1997; nr.
1.
52. Nilsson P. Svensk Diabetologi 1997 - några utvecklingslinjer. DiabetologNytt 1.
53. Nilsson P. Prevention av tobaksskador - varför räcker inte kunskap ? SLS.
Örebrodagarna 1997. Svenska Läkarsällskapets handlingar.
41

54. Nilsson P, Attvall S, Vessby B. Diabetes mellitus och lipidrubbningar - en terapeutisk utmaning (broschyr). MSD, 1997. (Reviderad 1999).
55. Nilsson P. Rökning ökar risken för blodfettsrubbning och diabetes.
Tobaksfronten 1997; nr. 1: 22.
56*. Brandström H, Nilsson P. Kvalitetssystem för kranskärlssjukdom - tidsträngd primärvård behöver kvalitetssäkringsstöd ! AllmänMedicin 1997; 18:133-34.
57*. Nilsson P, Hedblad B, Erhardt L, Hofman-Bang C, Rydén L. Angina pectoris en dyr folksjukdom- kräver genomtänkt ansvarsfördelning mellan öppen och sluten vård.
Läkartidningen 1998; 95:2430-6.
58*. Nilsson P. Biologiskt åldrande och apoptos - mekanismer för hjärtkärlsjukdom ?
(Summary in English). Nordisk Medicin 1998;113:82-84.
59. Nilsson P. Förord till boken C-M Stolt: Från kaos till kunskap. Medicinens historia till år 2.000.
Studentlitteratur AB. Lund, 1997.
60*. Nilsson P, Eriksson K-F, Groop L. Nya läkemedel mot insulinresistens.
Läkartidningen 1998; 95:2832-34.
61. Nilsson P. Biologiskt åldrande och prematur menopaus - modeller för en ökad kardiovaskulär risk. MEDIKAMENT 1997; 2:11-12.
62*. Nilsson P. Prematurt åldrande - modell för interaktion mellan arv och miljö.
Läkartidningen 1998; 95:3058-60.
63. Nilsson P. Apoptos vid hypertoni och hjärtkärlsjukdom. BLODTRYCKET
1997;13:91-5.
64*. Attvall S, Nilsson P. Riktlinjer om diabetes säkrar kvaliteten. Målet enhetlig vård, färre komplikationer. Läkartidningen 1997; 94:3243-5.
65. Svartholm R, Nilsson P. Stimulera den allmänmedicinska forskningen.
AllmänMedicin 1997 (suppl 21): 3-4.
66. Nilsson P. Från provinsialläkare till allmänläkare. Mänsklig nöd möts med god konsultation. Medicinskt Forum 1997; nr. 7:22-4.
67. Nilsson P. Ny bok om vuxendiabetes sätter patienten i centrum (recension).
DIABETES 1997; nr. 5: 12.
68. Nilsson P, Klasson E-B, Nyberg P. Projekt FÖREKOM: Icke-farmakologisk behandling av kardiovaskulära riskfaktorer i företagshälsovård - en 1-årig randomiserad interventionsstudie. (Stencil). Rapport till Helsingborgs stad, 1998.
69*. Nilsson P. Sociala faktorer och hjärtkärlsjukdom - en forskningsöversikt.
AllmänMedicin 1998; 19: 42-45.
70*. Nilsson P, Fritz T, Carlgren G. Det behövs ett nätverk för diabetesintresserade allmänläkare. AllmänMedicin 1998; 19:80-82.
42

71*. Sörman E, Nilsson P. Icke-farmakologisk behandling under ett år sänker HbA1c hos riskpersoner för typ-2 diabetes - en randomiserad studie i öppenvård. AllmänMedicin
1998;19:240-3.
72. Nilsson P. Social kris och ohälsa - ett primärvårdsperspektiv. Medicinskt Forum 1998: nr.3.
73*. Nilsson P. Allmänmedicinens medicinska historia - ett nytt forskningsfält. (Summary in English). Svensk Medicinhistorisk Tidskrift 1997; 1(suppl 1):39-44.
74*. Nilsson P, Haglund O. Evolutionsbiologiska perspektiv på hjärtkärlsjukdom.
Läkartidningen 1999;96:5630-2.
75. Nilsson P. Hypertoni vid diabetes mellitus. Bakgrund och behandling. Broschyr. MSD,
1998. Reviderad 2000.
76. Nilsson P, Eliasson M, Olsson B. Evidensbaserad primärvård. SBU - Vetenskap &
Praxis 1998; nr. 1:9.
77. Nilsson P. Konsultationen - en väg till nöjdare patient och bättre följsamhet ?
Medicinskt Forum 1998; nr 2:12-14.
78. Nilsson P. Evidensbaserad medicin på vårdcentralen - utvecklande utmaning eller utsiktslös utopi ? Primärvårdens Nyheter 1998; nr. 5:47.
79. Nilsson P. Kan kronisk infektion ge risk för hjärtinfarkt och hypertoni ? - Ett nytt forskningsfält. BLODTRYCKET 1998; 14:56-61.
80. Nilsson P. Prevention av hjärtkärlsjukdom i primärvård. Ingår i: Lindgärde F, Thulin T,
Östergren J (red.) Kärlsjukdomar – prevention och behandling . Studentlitteratur.
Lund, 2000.
81*. Nilsson P. Hur ser allmänmedicinens medicinska kärna ut ? - Behov av både sakkunskap och god konsultation. AllmänMedicin 1998;19:206-7.
82*. Nilsson P, Attvall S, Eliasson M. Aktivare terapi vid typ 2 diabetes motiveras av fynd i milstolpestudie. Läkartidningen 1998;95:4883-7.
83. Nilsson P, Attvall S. Bredda och skärp behandlingen! Läkartidningen
1998;95:5605-6.
84. Svartvik L, Nilsson P. Hälsa och känsla av sammanhang hos kvinnor i Lundabygden,
50-59 år. (stencil) Rapport. Institutionen för samhällsmedicinska vetenskaper. Lund,
1998.
85*. Nilsson P. Einar Sjövall - en rättsmedicinare i Lund med socialt patos. Nordisk medicinhistorisk tidskrift 1999;3:123-31.
86. Nilsson P. Eskil Kylin - den svenske fadern till det Metabola syndromet.
BLODTRYCKET 2000; nr. 3.
87. Nilsson P. Diabetessjukdomen. Komplikationer och behandling hos den äldre patienten. Nordisk Geriatrik. Äldremedicin inom primärvården. 1998; nr. 3:52-59.
43

88. Nilsson P. Nya riktlinjer för prevention av hjärtkärlsjukdom i Europa. KÄRiLET
1999;11:6-8.
89. Nilsson P. Nya riktlinjer för lipidbehandling. Primärvårdens Nyheter 1999;
Nr.5:68-70.
90. Nilsson P. Alkohol och det metabola syndromet. In: (red.) Bengt E. Karlberg. Vin, hälsa och hjärtkärlsjukdom.
Roche Läkemedel AB. Stockholm, 1999.
91*. Nilsson P. Evidensbaserad hypertonibehandling vid typ 2 diabetes. Nya studier stödjer aktiv blodtryckssänkning. Läkartidningen 2000;97:568-72.
92. Nilsson P. Öppnar tobaksbruk dörren till annat missbruk? Om missbrukets biologiska underlag och konsekvenser. MEDIKAMENT 1999:5:54-7.
93*. Fritz T, Carlgren G, Wändell P, Tovi J, Nilsson P. Typ-2 diabetes - en allmänmedicinsk angelägenhet som växer i betydelse. AllmänMedicin
1999;20:156-7.
94*. Håkansson J, Hellénius M-L, Nilsson P. Nya rekommendationer om behandling av hyperlipidemi. AllmänMedicin 1999;20:166-9.
95. Nilsson P. Hypertoni och dess behandling - ett manligt perspektiv. Medicinskt Forum
2000; nr. 2.
96*. Nilsson P. Hälsoekonomiska aspekter på primärprevention vid behandling av hyperkolesterolemi. Workshop: Behandling av hyperlipidemi . Information från
Läkemedelsverket 1999;10:72-3.
97*. Nilsson P. Oral vätskeersättning till diarrésjuka barn största livräddaren globalt sett.
Läkartidningen 1999;96:5761-2.
98. Nilsson P. Aktuellt om diabetes och hjärtat. Riskfaktorer, kardiomyopati och hjärtsvikt. RHC Bulletinen. 2000; nr. 1:6-13.
99*. Nilsson P, Nilsson J-Å, Lindgärde F. Kan viktnedgång avhjälpa fetmans problem?
Läkartidningen 2000; 97:2645-6.
100. Nilsson P. Blodtrycksbehandling hos äldre hypertoniker kan förebygga demensutveckling. Nordisk geriatrik 2000; nr. 2:9-15.
101*, Nilsson P. Utvecklingslinjer inom den nya kardiovaskulära genetiken. Läkartidningen
2000;97:3348-51.
102*. Nilsson P. Kalciumantagonisternas farlighet har inte kunnat beläggas. Har likvärdig effekt som konventionell behandling vid hypertoni. Läkartidningen 2000;97:3710-2.
103*. Nilsson P. Bertil Hood – en pionjär inom svensk hypertoniforskning (Summary in
English). Svensk Medicinhistorisk Tidskrift 2000;4(Nr. 1):149-53.
104. Nilsson P. Familjär förekomst av hjärtkärlsjukdom. Vilken nytta har man av anamneses för individuell riskbedömning? Svensk Cardiologi 2000;nr. 3:18-22.
105. Nilsson P. Utvecklingslinjer inom den nya kardiovaskulära genetiken. Kärilet 2000;12
(nr.3):4-8.
44

106. Nilsson P. Evidensbaserad medicin – Vad säger interventionsstudierna?
DiabetologNytt 2000; Nr. 4-5: 26-28.
107. Nilsson P. Hur går det för Diabetesnätverket för allmänläkare? DiabetologNytt 2000;
Nr. 4-5: 45.
108.* Nilsson P. Nya hypertoniriktlinjer bör anpassas till svenska förhållanden!
Läkartidningen 2000;97:5020-22.
109. Nilsson P. Vad är meningen med sex? – ett evolutionsmedicinskt perspektiv.
MEDIKAMENT 2000; nr. 7:24-28.
110.* Nilsson P. Vilka hypertonimedel är bäst? Resultatet av två nya meta-analyser berikar men avslutar inte debatten. Läkartidningen 2001;98:1082-3.
111.* Nilsson P. Livets biologiska triangel – samspel mellan nutrition, reproduktion och livslängd. Läkartidningen 2001;98:1797-1800.
112. Westling H, Nilsson P. Några blad ur medicinska fakultetens historia.
Ur: (Westling H. red.) BMC:s rötter. Lund, 2001.
113. Nilsson P. Vad beteendegenetiken kan lära oss. MEDIKAMENT 2001 (supplement); december: 65-7.
112. Nilsson P, Währborg P. Psykosocial stress och hjärtkärlsjukdom. Broschyr. Hässle
Mölndal, 2001.
113.* Nilsson P. Har postmodern teoribildning någon plats inom medicinen? Läkartidningen
2001;98:4860-3.
114.* Brandström H, Erhardt L, Hedbäck B, Israelsson B, Lingfors H, Nilsson P, Sjöberg G.
Kvalitetssäkring av sekundärprevention vid kranskärlssjukdom. Pågående projekt skapar möjlighet till förbättrad behandling. Läkartidningen 2001;98:4846-52.
115.* Nilsson P, Attvall S. Angiotensin II-receptorblockerarna minskar nefropati hos typ 2diabetiker. Tre nya studier intressanta, men besvarar inte alla frågor. Läkartidningen
2001;98:4960-2. Korrespondens Läkartidningen 2002;99:82.
116. Nilsson P, Werkö L. Den tidiga hypertoniforskningen i Sverige – en medicinhistorisk
översikt (Summary in English). Svensk Medicinhistorisk Tidskrift 2001;5:61-74.
117.* Nilsson P, Erhardt L. Stor engelsk studie: Statin sänker kardiovaskulär mortalitet och morbiditet. Läkartidningen 2001;98:5846-8.
118.* Rööst M, Nilsson P. Sömnbesvär - ett folkhälsoproblem. Potentiell riskfaktor för typ 2diabetes, insulinresistens, hypertoni, dyslipidemi och för tidigt åldrande.
Läkartidningen 2002;99:154-7.
119.* Nilsson P. Faktorer tidigt i livet kan påverka incidens av hjärt-kärlsjukdomar.
Läkartidningen 2002;99:642-4.
120. * Svartvik L, Lidfeldt J, Nerbrand C, Samsiö G, Scherstén B, Nilsson P. Hög känsla av sammanhang kan ha hälsofrämjande effekter. Läkartidningen 2002;99:1195-200.
45

121. * Nilsson P. Högt blodtryck 2002 - oftast riskfaktor och ibland sjukdomsyttring.
Läkartidningen 2002;99:1722-4.
122. * Nilsson P, Kahan T. Resultat från LIFE-studien: Lovande effekter av en ny klass hypertoniläkemedel. Läkartidningen 2002;99:1792-4.
123. * Nilsson P, Gudbjörnsdottir S, Cederholm J. Diabetes och tobak - dubbla hot mot hälsan. Läkartidningen 2002;99:2281-5.
124. * Nilsson P, Berglund G. Fetma är farligt - men vad händer vid viktnedgång?
Läkartidningen 2002;99:3178-81.
125. * Nilsson P, Attvall S, Weiss L. Ambitiösa amerikanska riktlinjer för riskfaktorkontroll vid diabetes. Har man lagt ribban alltför högt? Läkartidningen 2003;100:26-30.
126. * Nilsson P. ALLHAT - världens största behandlingsstudie för hypertoni. Stärker tiaziddiuretikas betydelse hos patienter över 55 år. Läkartidningen 2003;100:400-7.
127. * Nilsson P. Vaskulärt aktiva läkemedel kan förebygga typ 2-diabetes. Läkartidningen
2003;100:528-30.
128. * Nilsson P. Australisk studie drar andra slutsatser än ALLHAT: ACE-hämmare mer effektiva än tiazider hos äldre män med hypertoni. Läkartidningen 2003;100:1118-20.
129. * Attvall S, Eliasson B, Nilsson P. Ökad risk för hjärt-kärlsjukdom och diabetes hos psykiskt sjuka. Livsstilen en bidragande faktor. Läkartidningen 2003;100:2353-5.
130. * Nilsson P. Nytt europeiskt perspektiv på hypertoni och kardiovaskulära risker.
Läkartidningen 2003;100:3036-40.
131. * Nilsson P. Tre fjärdedelar av hjärtinfarktpatienter har störningar i sockeromsättningen. Läkartidningen 2003;100:3950.
132. * Nilsson I, Nilsson P. Medicinsk dokumentation genom tiderna. Läkartidningen
2003;100:4304-6.
133. * Nilsson P. Engelsk modell med öppen granskning av riktlinjer värd att pröva även i
Sverige. Läkartidningen 2004;101:1594.
134. * Nilsson P. Hypertoni - hett ämne för Läkartidningens skribenter. Från observationer och diet till kirurgi och stora kliniska läkemedelsstudier. Läkartidningen
2004;101:1598-603.
135. * Nilsson P. Medicinhistoria - bas för moderna läkare. Läkartidningen 2004;101:2158-9.
136. * Nilsson P. Sekundär prevention likvärdig för män och kvinnor efter hjärtinfarkt.
Läkartidningen 2004;101:2325.
137. * Nilsson P, Fagerberg B. Fetal programmering av ohälsa i vuxen ålder - arv eller miljö? Läkartidningen 2004;101:2342-5.
138. * Nilsson P. Värdet av VALUE - hypertonistudie som jämfört valsartan med amlodipin.
Nya data till stöd för tidig, optimerad blodtryckskontroll för högriskpatienter.
Läkartidningen 2004;101:2426-7.
46

139. * Gudbjörnsdottir S, Cederholm J, Nilsson P, Eliasson B, Berne C, Adamson U.
Nationella diabetesregistret 1996-2003. Kvalitetsvärdering visar att diabetesvården har förbättrats. Läkartidningen 2004;101:3790-7.
140. * Nilsson P, Attvall S, Båvenholm P. Lipidbehandling med statiner ger god prevention vid typ 2-diabetes. Interventionsstudier stärker stödet för aktiv behandling av riskpatienter. Läkartidningen 2004;101:3798-804.
141. * Nilsson P. Hur behandla hypertoni evidensbaserat men ändå individualiserat?
Kommentar till SBUs rapport om behandling av måttlig hypertoni. Läkartidningen
2004;101:4000-5.
142. * Nilsson P, Håkansson J. Amlodipin bättre än atenolol vid hypertoni. Förebygger mortalitet och kardiovaskulära händelser mer effektivt, visar ASCOT. Läkartidningen
2005;102:2922-3.
143. * Nilsson P. Primärprevention av hjärt-kärlsjukdom bör styras av skattning av absolut risk. Läkartidningen 2005;102:496-7.
144. * Nilsson P. Kardiovaskulär primärprevention måste gå på två ben. Både individåtgärder och folkhälsoåtgärder behövs. Läkartidningen 2005;102:783-5.
145. * Nilsson P. "Varför blir det inte som man tänkt sig?" Reflektioner kring svårigheterna att planera hälso- och sjukvård i Uganda. Läkartidningen 2005;102:1654-8.
146. * Nilsson S, Nilsson M, Nilsson E, Nilsson P. Långtidsöverlevnaden vid diabetes har successivt förbättrats. Lång sjukdomsduration kan ge information om protektiva möjligheter. Läkartidningen 2005;102:2066-70.
147. * Wide D, Nilsson P. Ett ständigt aktuellt läkaretiskt dilemma. Vems behov går först - patientens eller samhällets? Läkartidningen 2005;102:2410-2.
148. * Nilsson P, Fagerberg B. Metabola syndromet i blåsväder. Internationell strid om riskfaktorkomplexets vetenskapliga grund. Läkartidningen 2005;102:3202-3.
149. * Nilsson P. Trots tveksamheter kring betydelsen av fettintag: Livsstilsåtgärder är fortsatt viktiga för att förebygga hjärt-kärlsjukdom. Läkartidningen 2006;103:481.
150. Nilsson P. Farliga förbindelser – svensk-tyska nazimedicinska kontakter på 30-talet.
Sv Medicinhist Tskrf 2004; 8:217-228.
151. Appelquist M, Nilsson PM. Folkhälsan i östra Skåne 1860-1899 – en studie utifrån provinsialläkarrapporter. Sv Medicinhist Tskrf 2005; 9:95-114.
152. Levin A, Nilsson PM. Framväxten av en diagnos – synen på psykiska krigsreaktioner under 1900-talet med focus på FN-svenskarna I Kongo 1960-1964. Sv Medicinhist
Tskrf 2005; 9:163-186.
153. * Hemborg Kristiansson M, Stolt C, Nilsson P. Empatisk doktor eller kallhamrad yrkesman - läkaren i konsten. Läkartidningen 2006;103:3393-3396.
154. Hansson N, Nilsson PM. Läkare som medlemmar i Riksföreningen Sverige-Tyskland
1937-1945. Vilka och varför? Svensk Medicinhistorisk Tidskrift 2007; 11:151-164.
47

155.* Nilsson PM, Fyhrqvist F. Tidigt vaskulärt åldrande i relation till kort telomerlängd och
ökad kardiovaskulär risk – kommande möjligheter för behandling? Läkartidningen
2007 ;104:2801-5.
156. Nilsson PM, Bergkvist G, Peters A, Köpp W. 'Ärzteführerschule Alt-Rehse'--the main educational centre for promotion of Nazi medicine ideology in Germany during 1935 -
1943. Svensk Med Tidskr 2006;10:199-211.
157. Nilsson P. Ökad snusning bra för folkhälsan trots risk för pankreascancer.
Läkartidningen 2007;104:2415.
158.* Nilsson P. Bättre metoder behövs för effektiv rökavvänjning. Primärvården har viktig roll i det tobakspreventiva arbetet. Läkartidningen 2007;104:2412-3.
159. * Nilsson PM. Skärpt blodtryckskontroll krävs vid typ 2-diabetes. Interventionsstudien
ADVANCE ger tydliga besked. Läkartidningen 2007;104:3028-9.
160. * Berglund G, Nilsson PM, Leosdottir M. Fettintag och kardiovaskulär hälsa – är vi helt felinformerade? Läkartidningen 2007;104: 3780-3784.
161. * Nilsson P, Hansson N. Vissa eponymer etiskt tvivelaktiga. Viktigt ge den historiska bakgrunden för att stimulera kritiskt tänkande. Läkartidningen 2008;105:278-9.
162.
* Nilsson P, Eliasson B. Vad är egentligen en optimal behandling vid typ 2-diabetes?
Nya studier manar till eftertanke. Läkartidningen 2008;105:985-6.
163. * Nilsson P, Perk J, Rydén L. Dags för europeiskt perspektiv på kardiovaskulär prevention. Läkartidningen 2008;105:1000-4.
164. * Nilsson P. Nya hypertonistudier av stor betydelse för klinisk praxis. Även mycket gamla har nytta av blodtryckssänkning. Läkartidningen 2008;105:1382-4.
165. * Lindstedt I, Nilsson P. ABC om utredning och behandling av primär hypertoni.
Läkartidningen 2008;105:2107-12.
166. Nilsson P. Finanskrisen hotar folkhälsan - samhällsåtgärder behövs. Läkartidningen
2008;105:3053-4.
167. * Hansson N, Wistrand J, Nilsson P. Medeltidsläkaren blev en ikon för nazister och kommunister. Läkartidningen 2008;105:3146-8.
168. Groop L, Lyssenko V, Nilsson P. Nyupptäckta riskgener för diabetes typ 2 ökar förståelsen av patogenesen. Läkartidningen 2009;106:21.
169. * Hansson N, Bergkvist G, Nilsson P. Svenska läkare som gäster vid nazisternas elitskola. Läkartidningen 2009;106:301-3.
170. Nilsson PM. Kalciumantagonisterna – hur ser Furberg på dem nu?. Läkartidningen
2009; 106:607-8.
171. * Olsson A, Nilsson P. "Ju lägre LDL-kolesterol, desto bättre" gäller fortsatt.
Negativa/neutrala slutsatser av tre statinstudier ändrar inte klinisk praxis.
Läkartidningen 2009;106:854-7.
48

172. Nilsson P. Werkö Lars. Från blodhosta till vardagsstress. Sjukvård och medicinare i
1900-talets Sverige (Recension). Läkartidningen 2009;106:1205.
173. * Nilsson P. God effekt av blodtryckssänkning med ACE-hämmare plus kalciumantagonist . Läkartidningen 2009;106:103.
174. * Nilsson P. Medelhavskosten skyddar hjärtat. Ny systematisk genomgång ger ökat stöd för kostrekommendationer. Läkartidningen 2009;106:1959.
175. * Nilsson P, Attvall S. Intensiv glukoskontroll vid typ 2-diabetes lönar sig.
Läkartidningen 2009;106:2198.
176. Nilsson P. Ökat evidensunderlag för rosiglitazon . Läkartidningen 2009;106:2602.
177. * Cederholm J, Nilsson P, Eliasson B, Eeg-Olofsson K, Zethelius B, Gudbjörnsdottir S.
Samband mellan riskfaktorer och komplikationer vid diabetes. Rapport efter 13 år med Nationella diabetesregistret (NDR). Läkartidningen 2009;106:2684-9.
177. * Nilsson P, Eliasson B. Cancer är vanligare vid diabetes. Kanske spelar själva behandlingen också en roll. Läkartidningen 2010; 107:170-1.
178. * Nilsson P. Reviderade blodtrycksmål i nya riktlinjer. Systoliskt målblodtryck 130–139 mm Hg räcker för riskgrupper. Läkartidningen 2010; 107:18-9.
179. * Nilsson P. Sämre kognitiv funktion som barn - ökad hjärt-kärlrisk som vuxen.
Riskökning kan grundläggas redan i fosterlivet . Läkartidningen 2010;107:753-5.
180. * Lindstedt I, Nilsson PM. Pulstryck som markör för kardiovaskulär risk. Läkartidningen
2010; 210:107: 1474-6.
49